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 Abstract 
A randomized controlled field trial was designed to evaluate the effects of two treatment 
strategies on ceftiofur and tetracycline resistances in feedlot cattle.  The two strategies consisted 
of administering ceftiofur crystalline-free acid administration (CCFA) at either one or else all of 
the steers within a pen, and subsequent feeding/not feeding of therapeutic doses of 
chlortetracycline.  Both strategies were hypothesized to reduce ceftiofur resistance.  The effects 
of treatment strategies were evaluated via metagenome-based and culture-based assays. In this 
26-day study, 176 steers were allocated to 16 pens of 11 steers each.  The two strategies were 
randomly assigned to the pens in a two-way full-factorial manner resulting in four treatment 
groups.  The blaCMY-2, blaCTX-M, tet(A), tet(B), and 16S rRNA gene copies/g feces were 
quantified using qRT-PCR from fecal community DNA.  Antimicrobial susceptibility profiles 
were determined using microbroth dilution technique from the non-type-specific (NTS) E. coli 
isolates (n=1,050).  The NTS E. coli DNA was screened for the presence of blaCMY-2, tet(A), and 
tet(B) genes.  Pens in which all the steers received CCFA treatment showed an increase in 
blaCMY-2 and blaCTX-M log10 gene copies/g feces and in the proportion of ceftiofur-resistant and 
blaCMY-2 positive NTS E. coli.  This was in contrast to the pens where only one animal received 
CCFA treatment.  There was a significant decrease in quantities of tetracycline genes in 
community DNA in pens where all animals received CCFA treatment.  In contrast to 
metagenome-based assay results, culture-based assays indicated an increase in the proportion of 
tetracycline resistant NTS E. coli upon CCFA treatment.  Thereafter, chlortetracycline 
administration led to rapid expansion both of ceftiofur (blaCMY-2, blaCTX-M) and tetracycline 
[tet(A) and tet(B)] log10 gene copies/g feces.  Chlortetracycline treatment delayed the return of 
the ceftiofur resistance prevalence to baseline among NTS E. coli and thus did not lead to the 
hypothesized decrease in ceftiofur resistance.  Our data suggest that chlortetracycline use is 
contraindicated when attempting to avoid expansion of resistance to critically important 3rd 
generation cephalosporins in feedlot cattle.  Further studies are required to better establish the 
animal-level effects of co-housing antimicrobial-treated and non-treated animals together at 
varying ratios on the levels of antimicrobial resistance.  
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 Chapter 1 
Introduction 
 1.1.      Background 
Antimicrobial drug resistance is widely regarded to be a major public health threat [1].  
The science ministers of the G8 countries in June 2013 jointly declared “…antimicrobial drug 
resistance as a major health security challenge of the 21st century” [2].  The Centers for Disease 
Control and Prevention (CDC) in 2011 reported the estimated health care costs, and other 
societal costs, solely attributed to antimicrobial drug resistance in the United States to be 
approximately $20 billion per year and $34 million, respectively [3].  In addition, antimicrobial 
drug resistance is estimated to contribute more than 8 million additional hospital days incurred 
by patients in the United States [3].  There has been no new class of antimicrobial approved in 
more than 40 years to treat Gram negative bacillus infections [4].  Therefore, it is essential that 
we control antimicrobial drug resistance and preserve the efficacy of the existing antimicrobials 
used both in animal and human medicine.  This is particularly important in case of those drugs 
that have been identified as being critically important for human medicine [5].  
Third-generation cephalosporins (e.g., ceftriaxone) are presently classified as critically 
important drugs for human use.  Ceftiofur, an animal-only antibiotic, belongs to the same class as 
ceftriaxone and is extensively used in veterinary medicine and animal husbandry.  An association 
between ceftiofur usage in animals and ceftriaxone resistance among pathogenic bacteria in 
humans has been speculated upon in the past [6].  In order to safeguard animal and human 
health, the Food and Drug Administration (FDA) of the U.S. Department of Health and Human 
Services, in April 2012 released an order of prohibition restricting certain extra-label uses of 
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ceftiofur in animal agriculture [7].  There is an urgent need to better understand the complexity 
of resistance ecology in terms of selection and co-selection of resistance determinants or isolate 
phenotypes under specific antimicrobial selection pressures; further, there must be well-designed 
and thoroughly tested animal- and farm-level intervention strategies that can help control this 
global problem.  This work presented in this dissertation is focused on testing the multivariate 
impacts of two treatment strategies on ceftiofur resistance.  Both culture-based and metagenome-
based approaches were utilized in an effort to understand these resistance mechanisms both at 
genotypic and phenotypic levels. 
Differential ceftiofur crystalline-free acid (CCFA: Excede®, Zoetis Animal Health, NJ, 
U.S.A.) treatment, administered to either one or else all the steers within a pen, was the first 
strategy which was evaluated.  Animals within a pen are expected to exchange bacterial strains 
and resistant determinants (i.e., horizontal transmission) amongst each other via fecal-oral 
transmission (intermediated through the local environment) [8].  Untreated animals in a pen are 
likely to serve as a ready source of antimicrobial-susceptible bacterial strains for the treated 
animals in the same pen; these latter animals are far more likely to be harboring resistant bacteria 
during the post-treatment period.  Some scientists believe that resistance genes are associated 
with a fitness cost to the host bacterium, at least during the period immediately following the 
introduction of an antimicrobial to the market [9-10].  Readily available susceptible bacteria, 
from untreated pen mates, may outcompete and help to replace the resistant bacteria and promote 
re-colonization of the baseline microflora of the treated animal.  
The administration of chlortetracycline (CTC: Aureomycin®, Alpharma, Bridgewater, 
NJ) following treatment with long-acting ceftiofur (CCFA) was the second treatment strategy.  
This strategy was derived from the results of a previous study which demonstrated that 
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chlortetracycline treatment selected for a subset of the E. coli population that was resistant to 
tetracycline over the subpopulation that was co-resistant to tetracycline and ceftiofur [11].  
Hence, the proportion of ceftiofur-resistant E. coli significantly decreased upon chlortetracycline 
administration.  The present study was designed to evaluate this selective mechanism both 
among E. coli (qualitative phenotypic and genotypic analyses) and in the fecal metagenome as a 
whole (quantitative genotypic analysis only). 
 
 1.2.      Study objectives 
The objective of this randomized and controlled field trial was to investigate the effects 
of two treatment strategies on both ceftiofur and tetracycline resistance as measured qualitatively 
at both the phenotypic and genotypic isolate level, and quantitatively at the genotypic 
metagenomic level.  The two treatment strategies were: 
1. House either all CCFA (ceftiofur crystalline-free acid)-treated animals, or else one treated 
amongst all other untreated animals, together within a pen, mimicking metaphylaxis and 
individual therapeutic regimens, respectively. 
2. Feed therapeutic doses of CTC (chlortetracycline) following the earlier treatment with a 
long-acting ceftiofur formulation (CCFA). 
Metagenome-based (Chapter 3) as well as culture-based assays (Chapter 4) were utilized to 
evaluate the impact of these two strategies on both ceftiofur and tetracycline resistances within 
the bovine fecal microbiome. 
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Specific Objectives 
1. Perform gene quantification to estimate genotypic changes in enteric microbial 
populations as measured by variations in target gene copies [blaCMY-2, blaCTX-M, tet(A), 
tet(B), and 16S rRNA genes] in the fecal community DNA; before, during, and after the 
influence of these treatments.  Absolute target gene copies [blaCMY-2, blaCTX-M, tet(A), 
tet(B)] as well as these same quantities relative to 16S rRNA gene copies were each 
assessed separately. 
2. Determine phenotypic antimicrobial susceptibility to a panel of 15 different 
antimicrobials among non-type-specific (NTS) E. coli isolates by estimating and 
interpreting the minimum inhibitory concentrations.  In addition, screen the NTS E. coli 
DNA for the presence of tet(A), tet(B), and blaCMY-2 genes.  Further, evaluate the 
associations between treatment strategies, antimicrobial susceptibility data, and resistance 
genes (both quantitative and qualitative presence) to better understand the phenomenon 
observed in this as well as the earlier trial by Platt et al. (2008) [11].  
 
We hypothesized that these two treatment strategies would expedite the return of 
ceftiofur resistance to baseline (pre-treatment) levels among both fecal metagenomic DNA and 
commensal NTS E. coli as measured at the pen-level. 
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 Chapter 2 
Literature Review 
2.1.      Animal agriculture and antimicrobial usage 
An animal health report released by the United States Department of Agriculture (USDA) 
in March 2013 provided an overview of U.S. livestock and summary statistics on major 
commodities for the year 2011 [12].  According to the report, at the end of that year there were 
estimated to be approximately 100 million cattle (both beef and dairy) in the United States.  As 
of January 1, 2012, beef cattle constituted 76.4% of the total cattle inventory.  Economically, 
beef cows and calves were the largest commodity with the value of production being $45.2 
billion, followed by dairy, poultry, hogs, and sheep [12].  
Beef calves, after being weaned at approximately 7 months of age, generally are 
transported to backgrounder or stocker farms and thereafter to feedlots (or, feedyards) to be 
‘finished’ for slaughter.  Cattle are provided with high-energy rations in order to attain an 
acceptable size and carcass finish for slaughter.  Their stay in the feedlot lasts for an average of 6 
months, for those placed at around a year of age [13].  Antimicrobials are used in food-producing 
animals for reasons such as treatment, disease prevention, disease control, and growth 
promotion/improved feed efficiency.  Pneumonia and diarrhea caused by bacterial and viral 
agents both may cause significant morbidity and mortality.  In addition, prevention, control and 
treatment of conditions like liver abscess and other respiratory diseases is often required during 
cattle feeding period. Finally, antibiotics and other antimicrobials have been shown to increase 
weight gain and feed efficiency, even at very low sub-therapeutic doses [13].  A recent report 
(released March 2013) by USDA on management practices of feedlots presented summary 
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statistics on antimicrobial usage in feedlots with a capacity of 1,000 head or more [14].  
According to the report, 73.4% of feedlots used at least some antimicrobials in feed for their 
cattle, either for health or production purposes [14].  A previous 1999 survey report by USDA 
indicated that injectable antimicrobials that were commonly used metaphylactically to prevent 
shipping fever included tilmicosin (70.3%), oxytetracycline (31.9%), florfenicol (22.1%), 
penicillins (9.8%), and ceftiofur (8.1%).  Note that at that time CCFA (longer-acting ceftiofur) 
was not yet approved.  Chlortetracycline, tylosin, oxytetracycline, and 
chlortetracycline/sulfamethazine were administered in 51.9%, 20.3%, 19.3%, and 16.8% of the 
feedlots in either feed or water and for health or growth promotion purposes, respectively.  There 
were more than 50% feedlots that used florfenicol (54%), tilmicosin (51.7%), or tetracyclines 
(50.8%) for treating bovine respiratory disease complex (BRD) as a part of initial first-line 
therapy.  Feedlots also used cephalosporins (38.1%), fluoroquinolones (32.1%), penicillins 
(31.1%), and macrolides (17.4%) for initial treatment of respiratory diseases [15].  
In 2006, the FDA Center for Veterinary Medicine (FDA-CVM) reported that, since the 
inception of the agency, they had approved approximately 700 drug products for use in animal 
agriculture in the United States.  These drugs were approved to treat 2006 U.S food-animal 
population; the animals included: 8.8 billion chickens, 272 million turkeys, 97 million cattle, 59 
million pigs, and 7 million sheep along with a number of other minor food-producing animal 
species.  Additionally, more than 700 drugs products have also been approved for use in 
companion animals.  The 2006 U.S companion animal population has been estimated to consist 
of 60 million dogs, 75 million cats, and 5 million horses [16].  Many of the major antimicrobial 
drugs that are currently approved and marketed for animal agriculture are listed in Table 2-1 
[17].  
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 Antimicrobial Class Marketed Animals Drugs Human Medicine 
Aminocoumarins* Novobiocin - 
Aminoglycosides**** Dihydrostreptomycin - 
 Gentamicin H 
 Neomycin H 
 Spectinomycin H 
 Streptomycin H 
Amphenicols*** Florfenicol -a 
Cephalosporins†**** Ceftiofur -a 
 Cephapirin - 
Diaminopyrimidines* Ormetoprim - 
Fluoroquinolones**** Danofloxacin - a 
 Enrofloxacin -a 
Glycolipids* Bambermycins - 
Ionophores* Laidlomycin - 
 Lasalocid - 
 Monensin - 
 Narasin - 
 Salinomycin - 
Lincosamides*** Lincomycin H 
 Pirlimycin -a 
Macrolides**** Erythromycin H 
 Gamithromycin - 
 Tilmicosin - a 
 Tulathromycin - 
 Tylosin -a 
Penicillins†**** Amoxicillin H 
 Ampicillin H 
 Cloxacillin H 
 Penicillin H 
Pleuromutilins*** Tiamulin - 
Polypeptides** Bacitracin H 
Quinoxalines* Carbadox - 
Streptogramins*** Virginiamycin -a 
Sulfas*** Sulfadimethoxine -a 
 Sulfamerazine -a 
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 Sulfamethazine -a 
 Sulfaquinoxaline -a 
Tetracyclines*** Chlortetracycline -a 
 Oxytetracycline H 
 Tetracycline H 
 
Table 2-1 Antimicrobial classes and products marketed for use in food-producing animals 
in the United States as of 2013 and the corresponding usage in human medicine 
Adapted from [5, 17-18] 
****: Critically important antimicrobials 
***  : Highly important antimicrobials 
**    : Important antimicrobials 
*      : Unclassified 
†      : 1st and 2nd generation cephalosporins are classified as highly important antimicrobials 
whereas 3rd and 4th generation antimicrobials are classified as the critically important 
antimicrobials; similarly anti-staphylococcal penicillins are classified as highly important 
whereas natural aminopenicillins and antipseudomonal penicillins are classified as critically 
important antimicrobials by WHO 
a          : Closely related analogues are important in human medicine 
H     : Marketed human drugs 
 
There are both risks and benefits accruing from the use of antimicrobials in animal 
agriculture; that is, environmental, animal and human health risks associated with the 
development of antimicrobial resistance and other effects relating to residues and metabolites, as 
well as economic and welfare benefits.  Some benefits of antimicrobials include reduced 
morbidity and mortality, improved feed efficiency resulting in an increase in daily weight gain 
and reduction in feed inputs per unit animal produced, increased production efficiency resulting 
in reducing the number of animals required to produce given amount of animal product such as 
beef; reduction in the resources required to produce feed such as land (additional 2 million acres 
required if the use of antimicrobials as growth promoters is withdrawn), fertilizers, insecticides, 
and gasoline; reduction in the amount of manure per unit animal product; and reduced consumer 
cost per unit animal product (increase by $5-10 per capita per annum required if the use of 
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antimicrobials as growth promoter is withdrawn) [19-22].  According to several authors, the 
benefit-risk ratio should be taken into account to determine the overall impact of antimicrobials 
on the health of animals/humans, and the environment. 
In order to track antimicrobial usage trends in food-producing animals and to examine the 
relationship of these trends to antimicrobial resistance, the FDA introduced Section 105 of the 
Animal Drug User Fee amendments in the year 2008 [23].  This legislation mandated that 
sponsors of approved antimicrobial drugs report their total antimicrobial product sale 
information to the FDA.  This does not summarize the antimicrobial amount purchased by the 
end user or utilized in animals; however, it may be used as an estimate or surrogate of the same.  
The legislation also directed the FDA to issue annual summaries of the information reported 
from sponsors to the public; albeit, while protecting proprietary commercial sale information for 
those products with a very limited number of sponsors.  Annual totals of antimicrobial sales, and 
distribution summaries by antimicrobial drug class, for the years 2009, 2010, and 2011 are 
presented in Table 2-2 [17, 24-25].  Approximately 13.1 million, 13.2 million, and 13.5 million 
kilograms of antibacterial drugs were sold for the use in food-producing animals in the years 
2009, 2010, and 2011, respectively. 
Sales data for human medicine for 2009, 2010, and 2011 as released by the FDA are also 
summarized in Table 2-2 [26-27].  These data provide an estimate of antimicrobials sold from 
the manufacturers to various channels of distribution (outlets).  They are not a direct estimate of 
antimicrobials sold or administered to patients directly.  These data may be used as surrogates of 
human antibacterial drug use in the U.S. market; albeit, with great caution.  With some minor 
variability, sales were flat and at approximately 3.3 million kilograms of antibacterial drugs sold 
in the years 2009, 2010, and 2011. 
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The data clearly suggests that the total amount of antimicrobials distributed for use in 
food-producing animals is approximately four times higher than that used in human medicine.  
However, FDA cautioned the direct comparisons between the quantities of animal and human 
sales data [28].  Some variables to be considered before such comparisons are made include the: 
physical characteristics like weight of humans and animals, differences in antimicrobial dosage 
and duration of requirements between animals and humans, purpose of antimicrobial use in 
humans (disease prevention or treatment) versus animals (treatment, control, prevention, and 
growth promotion), and the number of humans versus animals [28].  
 
Antimicrobial 
Class 
Animals (kgs) Humans (kgs) 
2011 2010 2009 2011 2010 2009 
Aminoglycosides 214,895 200,794 339,678 6,485 6,991 9,381 
Cephalosporins 26,611 24,588 41,328 496,910 502,561 499,616 
Ionophores 4,123,259 3,821,138 3,740,627 NA NA NA 
Lincosamides 190,101 154,653 115,837 71,455 69,235 69,737 
Macrolides 582,836 553,229 861,985 164,028 164,309 176,278 
Penicillins 880,163 870,948 610,514 1,460,421 1,439,930 1,459,219 
Sulfas 371,020 506,218 517,873 481,664 479,484 471,442 
Tetracyclines 5,642,573 5,592,123 4,611,892 113,832 129,183 131,137 
Others 1,510,572 1517447 2,227,366 494,381 487,213 500,096 
Total 13,542,030 13,241,138 13,067,100 3,289,176 3,278,906 3,316,906 
 
Table 2-2 Total mass of antimicrobials (kgs) sold and distributed for food-producing 
animals and humans through retail and non-retail channels in the United States (2009-
2011) 
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2.2.      Cephalosporins and bacterial resistance mechanisms 
 Cephalosporins belong to the β-lactam class of antimicrobials.  Cephalosporins were 
introduced into human medicine in 1964.  They have been extensively used in human medicine.  
They are the third most common category of antimicrobials (after penicillins and macrolides) 
prescribed in the United States in outpatient settings for humans.  In 2010, cephalosporins made 
up 14% of the total out-patient prescriptions; this accounted for approximately 36.2 million 
prescriptions per year in the United States [29].  Human sales data released by the FDA suggest 
that approximately 0.5 million kgs of cephalosporins are sold or distributed each year in the 
United States (Table 2-2).  The 3rd generation cephalosporins are categorized as critically 
important antimicrobials for human use [5].  As such, they are used to treat critically ill patients 
with life threatening diseases such as severe and invasive Salmonella and Shigella infections, 
particularly in children and pregnant women.  This is significant because fluoroquinolones 
interfere with cartilage formation in children/fetuses and thus should not be used in children and 
pregnant women [7, 30]. 
The mechanism of action of cephalosporin drugs is to interfere with the final stages of 
bacterial cell wall synthesis, thereby increasing the permeability and thus leading to hydrolysis of 
the bacterial cell.  These antimicrobials bind to enzymes called penicillin-binding proteins (PBP; 
a transpeptidase) and form an irreversible bond with the enzyme, thereby inactivating it.  This 
enzyme plays a major role in building the peptidoglycan, which is a component of the cell wall 
[31]. 
Ceftiofur and cephapirin are two cephalosporin drugs that are presently approved for use 
in animal agriculture in the Unites States [7].  Ceftiofur is a third generation cephalosporin.  It 
was licensed for therapeutic use in animal agriculture in 1988 [32].  It was first licensed as a 
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short-acting formulation requiring reconstitution (Naxcel®) followed by a slightly longer 
duration and more convenient formulation in 1996 (Excenel®), and then in 2003 as an even 
longer acting ceftiofur crystalline-free (CCFA) formulation called Excede® (Zoetis Animal 
Health, NJ, U.S.A.).  Excede® is now marketed for use in beef cattle, dairy cattle, pigs, and 
horses. Presently, ceftiofur is used as an injectable product to control or treat respiratory diseases 
and to treat foot rot (bovine interdigital necrobacillosis) in beef cattle [7].   
Generally, there are 3 major mechanisms by which bacteria can develop and express 
resistance: (1) efflux of the antimicrobial agent or alterations in the bacterial cell permeability, 
(2) enzymatic or other inactivation of the antimicrobial agent, and (3) decreasing access of the 
agent to the antimicrobial target enzymes (PBP’s) [33-34].  Enzymes called β-lactamases are 
utilized by Gram negative bacteria to inactivate cephalosporin drugs by disrupting the β-lactam 
ring and thereby inactivating the drug.  Alteration in PBP is the main mechanism of β-lactam 
resistance in Gram positive bacteria, examples of which are the PBP5-mediated resistant 
Enterococcus species and the PBP2a-mediated methicillin-resistant Staphylococcus aureus [34].  
Ambler’s molecular classification has been used to categorize the β-lactamases into 4 
classes (classes A, B, C, and D).  This is a classification based on sequence similarities.  Classes 
A, C, and D group enzymes are serine enzymes while the class B is comprised of metallo β-
lactamases [34-35].  Third generation cephalosporin resistance can occur via AmpC β-lactamases 
(class C), extended-spectrum beta-lactamases (ESBLs) (class A; e. g. CTX-M family, and SHV 
or TEM derivatives), OXA ESBLs (class D), or carbapenem-hydrolyzing β-lactamases (class A 
and B) [36].  The two most important classes of β-lactamase enzymes for cephalosporin 
resistance are the AmpC cephalosporinases and the ESBLs.   
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The plasmid mediated β-lactamase cephamycinase-2 (blaCMY-2) enzyme belongs to the 
AmpC cephalosporinase group of enzymes.  Discovery of this Amp C plasmid-encoded blaCMY-2 
gene occurred in Greece in 1990 from a Klebsiella pneumoniae isolate.  Resistance among 
Salmonella spp. from cattle attributed to blaCMY-2 in the United States was first documented in 
1998 [37].  The plasmids (as opposed to chromosomes) encoding the blaCMY-2 gene are 
predominantly associated with ceftiofur resistance in Salmonella isolates, both from humans and 
animals, in the United States [31, 34, 38].  In the United States, the plasmid harboring blaCMY-2 
gene almost always appears to harbor other antimicrobial resistance genes [39-41].  There have 
been many studies that have identified associations among blaCMY-2 gene and several other 
tetracycline genes [42-45].  The gene has also been associated with integrons/transposons, 
therefore readily aiding in the horizontal dissemination of the gene among various enteric 
bacteria [34]. 
A chromosomally located ampC β-lactamase gene has been discovered in E. coli, but has 
so far not been detected in Salmonella [34].  The ampC gene is suggested to be a structural gene 
for the enzyme; ampC positive strains possess very sparse β-lactamase activity [46-47].  The role 
of this gene in enhancing β-lactamase activity requires further investigation.  Point mutations in 
the ampC operator or promoter region are found to render resistance towards cephalosporin 
drugs by over expressing the ampC β-lactamase gene [33].  
Extended-spectrum β-lactamases (ESBL) have not been detected among the Salmonella 
isolates collected from food-producing animals by NARMS as of the  2011 report [33].  
However, they have been widely found in Europe and the rest of the world.  The CTX-M 
enzymes are one of the families of ESBLs that are encoded on plasmids.  They have a 
preferential ability to hydrolyze cefotaxime and thus the acronym [36].  Overall, the enzyme 
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substrates include penicillins, cephalosporins including oxyiminocephalosprins, and 
monobactams [34].  Worldwide, the CTX-M family of enzymes are the most widespread ESBLs 
among both animal isolates [34] as well as human isolates [48-49].  The CTX-M type enzymes 
have been reported in United States in humans [50-51].  However, in food-producing animals the 
reports of genes coding for CTX-M type enzymes are rare and require careful sample enrichment 
to identify; that is, they do not appear in non-selective media or in surveillance isolates from 
clinical or non-clinical sources [52-53].  The substrate specificity of ESBLs is relatively broad 
and therefore they can hydrolyze a variety of β-lactam antimicrobials in contrast to AmpC 
cephalosporinases [34].  The plasmids harboring blaCTX-M genes are also associated with 
multidrug resistance; they are commonly found to be associated with blaTEM genes as well as 
aminoglycoside, chloramphenicol, sulfonamide, tetracycline, and trimethoprim resistance genes 
[34, 54-56]. 
 
2.3.      Tetracyclines and bacterial resistance mechanisms 
Tetracyclines were first approved by the FDA in 1948 for therapeutic use in humans [57].  
Presently, in the United States, tetracyclines constitute 8% of total prescriptions, which in turn 
represent approximately 20.7 million prescriptions per year in human medicine [29].  Human 
sales data released by the FDA suggest that approximately 0.1 million kgs of tetracyclines are 
sold or distributed each year in the United States (Table 2-2).  Tetracyclines have been classified 
as highly important antimicrobials for human use [5].  These are broad spectrum bacteriostatic 
drugs, that are active against a wide array of Gram negative and Gram positive pathogens, 
protozoan parasites, and other atypical organisms (Chlamydia, Mycoplasma, and Rickettsia) [58].  
The tetracycline drugs, at therapeutic concentrations, bind to the 30s subunit of the ribosome, 
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thereby preventing the aminoacyl-tRNA from attaching to the ribosomal acceptor (A) site, 
resulting in inhibition of bacterial protein synthesis [58-59]. 
  Tetracycline, chlortetracycline, and oxytetracycline are the core tetracycline drugs that 
are marketed for use in food-producing animals.  In food animals, these drugs are utilized to 
combat bacterial enteritis, bacterial respiratory infections, liver abscess, and also vector borne 
infections (e.g. rickettsiosis and borreliosis).  In addition, they are used as growth promoter 
agents in cattle, poultry, and swine [60].  The total quantity of tetracyclines sold or distributed 
for animal agriculture purposes amounted to approximately 5.6 million kilograms in the year 
2011 (Table 2-2). 
 The mechanisms by which the bacteria can develop resistance against tetracycline 
antimicrobials are (1) efflux of the tetracycline drug, thereby reducing the drug concentration in 
the bacterial cytosol, (2) enzymatic alteration of tetracycline drugs, and (3) ribosomal protection 
mechanisms that affect the binding of tetracyclines to the bacterial ribosome.  Data from the 
2010 U.S. National Antibiotic Resistance Monitoring System (NARMS) indicated that 11% and 
33.6% of the non-Typhi Salmonella isolates arising from human clinical cases and food-
producing animals at slaughter, respectively, demonstrated decreased susceptibility towards 
tetracyclines.  Among human isolates, these were the lowest resistance levels recorded since 
1999; in contrast, these were among the highest resistance levels recorded for food-producing 
animals (Figure 2.1).  As of 2001, there were approximately 29 tetracycline resistance genes (tet) 
and 3 oxytetracycline genes (otr) that had been characterized.  Out of these 32 genes, 18 tet 
genes and one otr gene code for an efflux pump; while seven tet genes and one otr gene code for 
proteins that aid in ribosomal protection; one tet gene [tet(X)] code for enzymatic inactivation of 
drug molecule; and mechanism of resistance for one tet and one otr genes are not established yet 
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[58].  Among food-producing animals, tet(A), tet(B), and tet(C) are the most abundant 
tetracycline resistance genes detected [61-63].  All three genes confer resistance by coding for 
membrane associated proteins that transport the tetracycline molecules outside of the bacterial 
cell [58].  Tetracycline resistance is very often associated with co-resistance towards other 
antimicrobials [63].  The tetracycline resistance genes tet(A) and tet(B) are typically found to be 
negatively correlated with each other’s presence, while tet(C) can be found with either of the 
others [62-64]. 
 
2.4.      Transfer of antimicrobial resistance from animals to humans 
Historically, transferable mechanisms of resistance to antimicrobial agents were 
demonstrated by the Japanese as early as 1959 [65-67].  Consequently, the worldwide scientific 
community started to observe more carefully the non-therapeutic usage of antimicrobial drugs in 
food animals [68].  The Joint Committee on the Use of Antimicrobials in Animal Husbandry and 
Veterinary Medicine (established in 1968) presented the ‘Swann Report’ to the British 
Parliament in November 1969 [69].  In this report, antimicrobial use in food-producing animals 
was reported to be the cause of a drastic increase in resistant bacteria in animals over the 
preceding decades.  Such resistance was found to be transferable to human bacteria and therefore 
could pose a public health risk.  Ongoing debate concerning the continued use of antimicrobials 
in animal agriculture, especially regarding threats to human health, was initiated by this report in 
UK [69].  This debate continues to the present.  The acquisition of antimicrobial-resistant 
bacteria by humans has been thought to occur via a variety of routes [20, 70].  Some suggested 
routes of transmission are: meat products contaminated at slaughter, animal and human fecal 
waste contamination of the environment, and direct animal-human contact [20, 70].  Several 
studies have demonstrated the transfer of antimicrobial resistant bacteria through direct contact 
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with animals or their manure [71-72], indirect contact via food contamination by animal-derived 
bacteria (e.g., Salmonella and Campylobacter) [73], or from person-to-person contact following 
primary exposure of farm workers to animals [74].  
 There is increasing concern about the use of antimicrobials in animal production systems 
as this may increase antimicrobial resistance to drugs used in human medicine.  This led the 
World Health Organization (WHO) to categorize and prioritize the antimicrobials into ‘critically 
important’, ‘highly important’, and ‘important’ based on the importance of the antimicrobial 
drug for treating human diseases (Table 2-1) [5].  This provides a reference for the prudent use of 
antimicrobials in humans and animals that are critically important for human medicine. 
 Several reviews of the scientific literature regarding the evidence of use of antibiotics in 
food animals leading to increase in resistance among humans have been published [20, 70, 75].  
A substantial amount of the data demonstrating such a linkage comes from: 1) case studies where 
the reported infection is traced backwards to a farm or higher risk groups such as farm workers, 
2) experimental studies demonstrating the transfer of resistant determinants among gut flora, and 
3) microbiological and molecular ecological studies of bacterial isolates from humans, food 
animals, and retail meat.  Resistant pathogen transfer from animals to humans has attracted the 
most attention for studies investigating antimicrobial-resistant bacterial ecology [74, 76-77]; 
however, commensal bacteria make up the vast majority of the gut flora and function as a 
reservoir of resistance genes and thus can transfer resistance to the pathogenic bacteria (reservoir 
hypothesis) [78].  Zoonotic as well as commensal bacteria are frequent carriers of transferable 
resistance genes and can transfer and colonize successfully from the GI tract of the animals to the 
human gut [79-83].  Also, studies with humans have shown that ingested animal bacteria have 
transmitted their resistance genes to the normal flora and pathogens of the human GI tract [84-
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85].  Therefore, one opinion is to use a wide variety, or else a more predominant bacterial species 
like Bacteroides and Gram-positive colonic anaerobes to study the impact of antimicrobial use in 
animals and humans [78, 86].  Another opinion is to study the ecology of resistance genes rather 
than resistant bacterial strains as the resistance genes are thought to readily move among various 
strains [78]. 
Results from a USDA nationwide survey in 1994 indicated that 15% of the beef carcasses 
were contaminated with one or more species of disease-causing bacteria [87].  Another survey 
indicated that 30% of chicken products were contaminated with viable Salmonella and 60-80% 
of the chickens were contaminated with Campylobacter; of which, many strains were resistant to 
common antibiotics [88].  However, it remains exceedingly difficult to track and document the 
exact link between animal antimicrobial use and subsequent transference of resistance to the 
humans [20, 89-91].  There are many opportunities from the farm to the table (e.g., production 
sites, processing, packaging plants, and transport depots) for the bacteria carrying resistance 
determinants to enter the food chain.  In addition, there are other factors that likely play a role; 
for example, consider the actions of individuals operating before and after the food harvest – 
improper storage, poor home sanitary practices, or improper cooking.  Therefore, a low 
likelihood of transfer of resistant bacteria from animal to human is suggested by some [90].  
Dietary and occupational human history are not the sole variables that determine the 
antimicrobial resistance transfer; other variables like international transport of animals, humans, 
feedstuffs, and food products all play an important role in dissemination of resistant strains or 
determinants.  Therefore, it is extremely difficult to have a valid exposure assessment in this 
case.  It is important to quantify the actual risk of antimicrobial resistance transfer; so far, this 
risk seems low.  However, the continued and cumulative effects on the animal populations of 
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antimicrobial use means that even low risk, but frequent events, and an increasing hazard can 
pose problems over time [89]. 
Ecological studies demonstrating the correlation between resistant strains obtained from 
animal and human infections are often used as evidence of causation for transfer of resistant 
organisms from animals to humans [92].  While this may well be true, the directionality of 
transmission should also be carefully considered before drawing causal inferences based on 
ecological correlation studies.  It is possible that humans select for resistant organisms and these 
are further disseminated to animals [93].  The antimicrobial resistance issue involves entire 
ecosystems where resistant organisms or resistant determinants keep flowing constantly among 
different environments [91].  A better understanding of background levels of antimicrobial 
resistant organisms and their genes is needed to conclude the directionality of flow of resistance 
from animals to humans or vice versa and also the impact of use of antimicrobials in animals on 
human health [91]. 
 
2.5.      Economic impact due to antimicrobial resistance 
The Centers for Disease Control and Prevention (CDC) in the year 2011 reported the 
national annual estimates for number of illnesses, hospitalizations, and deaths among humans 
caused by 31 major known pathogens [94].  The estimates were largely derived from laboratory 
based surveillance data from 2000-2008 reported through 5 surveillance programs: the 
Foodborne Diseases Active Surveillance (Food-Net), the National Notifiable Diseases 
Surveillance Systems (NNDSS), the Cholera and Other Vibrio Illness Surveillance (COVIS), the 
National Tuberculosis Surveillance System (NTSS), and the Foodborne Disease Outbreak 
Surveillance System (FDOSS).  All of the estimates were based on the United States population 
in 2006 (299 million people).   
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It was estimated that these 31 pathogens caused 37.2 million illnesses, 228,744 
hospitalizations, and 2,612 deaths annually in the United States.  Of these, 9.4 million illnesses, 
55,961 hospitalizations, and 1351 deaths annually were due to food-borne sources [94].  The 
second major cause of foodborne illnesses after noroviruses (58%) was found to be non-
Typhoidal Salmonella species (11%; 1.03 million cases).  Non-Typhoidal Salmonella were found 
to be the foremost leading cause of hospitalizations due to food borne pathogens (35%) and also 
deaths (28%).  Similarly, Campylobacter species were among the leading causes of foodborne 
illnesses (9%; 0.85 million cases) and hospitalizations (15%) [94].  Both non-Typhoidal 
Salmonella and Campylobacter species are considered zoonotic pathogens.   
Antimicrobial usage in food-producing animals has been debated over the last several 
decades since food of animal origin may act as a vehicle to carry resistant food borne pathogens 
and genetic resistance material.  There can be a major public health impact if significant 
percentages of these zoonotic pathogens develop resistance to the antimicrobials that are 
currently being used in human medicine [95]. 
The CDC in 2013 reviewed the data obtained from outbreak-associated illnesses from 
1998-2008 in order to attribute food borne illnesses, hospitalizations, and deaths annually to 17 
food commodities in the United States.  Among bacterial infections, beef contributed to 13.4% 
(482,199 cases) of illnesses, 7.4% (2640 cases) of hospitalizations, and 5.9% (51 cases) of deaths 
[96].  
The CDC also provided cost estimates of food borne illnesses in humans caused by the 
combined 31 identified pathogens and a broad category of unspecified agents [97].  The annual 
economic burden estimates were modeled based on the estimate provided by CDC [98].  The 
average cost per case of a food borne illness was $1,626.  The annual estimated cost due to 
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health losses from food borne illnesses was as high as $77.7 billion [98].  The illnesses caused by 
resistant pathogens can fail to respond to antimicrobial treatment (where indicated) and may 
prolong the illness, lead to an unfavorable prognosis, and increase in-hospital treatment days.  
This increases the financial burden to health care systems and society [99].  Older annual cost 
estimates of illnesses caused by resistant bacteria in 1998 by the Institute of Medicine were 
approximately $4 to $5 billion [100].  In 2003, the CDC estimated the annual ‘dead-weight’ loss 
due to resistance (costs incurred by the antibiotic resistance in excess of the benefits obtained by 
using antibiotics more than the maximum welfare levels) associated with outpatient amoxicillin 
prescriptions to be $225 million [101].  A single hospital study in Chicago in 2008 estimated the 
cost associated with antimicrobial-resistant infections.  The costs and mortality attributable to 
occurrence of antimicrobial-resistant infections were approximately $21,000 per infected patient 
and 6.5% of deaths, respectively [102].  
 
 2.6.      Antimicrobial resistance surveillance in food animals 
The National Antimicrobial Resistance Monitoring System (NARMS; formerly known as 
National Antimicrobial Susceptibility Monitoring Program) was established in 1996.  It is a 
collaborative effort of the U. S. Food and Drug Administration (FDA), the U. S. Department of 
Agriculture (USDA), and the U.S. Centers for Disease Control and Prevention (CDC).  This 
national public health surveillance system prospectively monitors the changes in the resistance or 
susceptibility patterns among select enteric zoonotic pathogens and commensal organisms from 
human and animal diagnostic samples, healthy farm animals, and retail meat at slaughter and 
processing [103].  Resistance to a wide range of antimicrobials is tested on the basis of their 
importance in human and animal medicine.  Initially in 1996, non-Typhoidal Salmonella was 
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chosen as the sentinel bacteria to study resistance patterns among enteric bacteria.  In 1998, 
Campylobacter was introduced to the animal arm of NARMS.  Later in 2000, E. coli and 
Enterococcus were also added to the list of organisms to be monitored [13].  The testing is still 
restricted to Salmonella spp. for the cattle samples. 
The descriptive data generated by NARMS helps to identify the trends of existing, 
detection of emerging, antimicrobial resistance in animals and humans.  This aids in providing 
timely information to veterinarians, human doctors, and regulatory bodies like the FDA which 
has proven instrumental in promoting interventions, research, and legislative decisions that may 
reduce the antimicrobial resistance among enteric food borne bacteria [104].  
There are important factors to be considered before interpreting the NARMS results.  
Factors include inherent sampling bias and test methodologies [13, 39].  An external 
subcommittee of the Science Board to the FDA reviewed the data obtained through the NARMS 
program in 2007 [104].  They expressed concerns about sampling bias in both animal and human 
arms.  The animal arm utilized Salmonella isolates that came from clinically ill animals, healthy 
animals, and animals at slaughter to study resistance trends.  The human arm of NARMS relies 
solely on public health laboratory-based surveillance.  Only clinical isolates are tested for 
susceptibility profiles.  There is a serious concern about extrapolating these results to the general 
animal and human population of the United States.  Prior treatment bias could severely affect the 
external validity of the results at the national level [39].  In response to making the samples more 
representative of the U.S. animal population, NARMS discontinued the analysis of diagnostic 
Salmonella isolates from sick animals.  The human clinical isolates are still analyzed.  However, 
the committee suggested also including isolates from healthy humans in the sampling [39].  The 
present methodology to test isolates is limited to phenotypic culture-based approaches.  The 
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committee suggested that NARMS ought to expand their methodology to incorporate molecular 
methods for gene detection from samples irrespective of bacterial species or whether the gene is 
present in a pathogen or a commensal organism [104].   
The sole reliance on culture-based approaches has been criticized since it may lead to 
selection of only a subpopulation, processing particular phenotypic and genotypic characteristics, 
and therefore does not represent the entire bacterial population and especially the un-culturable 
bacteria [13, 105]; further, antimicrobial genes may not be expressed or may be lost under the 
selection pressure of the media [106].  In contrast to the culture-based approaches, a 
metagenome-based approach enables the researcher to screen all the bacterial species from the 
samples, since community DNA represents the entire gene pool.  However, information about 
the presence of a particular gene in specific bacterial species cannot be identified [105-106] from 
such analyses.   
Data from the 2010 U.S. National Antibiotic Resistance Monitoring System (NARMS) indicate 
that 2.8% of the non-Typhi Salmonella isolates arising from human clinical cases were resistant 
to both ceftiofur and ceftriaxone.  At the same time, 21.5% of the non-Typhi Salmonella isolates, 
obtained from food-producing animals at slaughter, were resistant to both ceftiofur and 
ceftriaxone.  This is in sharp contrast to the 14.5% of the non-Typhi Salmonella animal isolates 
that were resistant in 2009.  The prevalence of ceftriaxone resistance among human isolates has 
been observed to be relatively stable since 2004; however, in 2010 ceftriaxone resistance among 
non-Typhi Salmonella cattle isolates (22%) was observed to be at its highest since NARMS 
testing began in 1997 (Figure 2.1) [107].  Caution should be employed while comparing the data 
from before and after 2006, especially from cattle sources, since clinical samples were not 
considered for susceptibility testing after the year 2006.  However, the trend clearly shows an 
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ongoing increase in ceftiofur and ceftriaxone resistance (a critically important 3rd generation 
cephalosporins) among the cattle isolates.
 
Figure 2.1 Percentage of Salmonella isolates resistant to ceftiofur, ceftriaxone, and 
tetracycline among cattle and humans isolates analyzed by the National Antimicrobial 
Resistance Monitoring System (NARMS) from 1999-2010.   
Legend key: tio_human represents percentage of human isolates resistant to ceftiofur, 
tio_cattle represents percentage of cattle isolates resistant to ceftiofur, axo_human 
represents percentage of human isolates resistant to ceftriaxone, axo_cattle represents 
percentage of cattle isolates resistant to ceftiofur, tet_human represents percentage of 
human isolates resistant to tetracycline, and tet_cattle represents percentage of cattle 
isolates resistant to tetracycline. 
 
2.7.      Regulatory bodies and their actions to control antimicrobial resistance 
Over the years, based on the scientific literature and the surveillance data gathered from 
NARMS (since 1997), the FDA has released several guidance documents to help control 
antimicrobial resistance in human medicine that may be caused by the use of antimicrobials in 
0
5
10
15
20
25
30
35
40
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Pe
rc
en
t r
es
is
ta
nt
 is
ol
at
es
 (%
) 
Year 
tio_human
tio_cattle
axo_human
axo_cattle
tet_human
tet_cattle
24 
 
animal agriculture.  While not mandated, a guidance document consists of the FDA’s current 
view on a subject and it recommendations to the animal pharmaceutical industry.  
Subsequent to the Swann report in U.K. in 1969, indicating the possibility of transfer of 
antimicrobial resistance from animals to humans; the FDA in 1970 established a task force of 
scientists to perform a comprehensive review of the use of antimicrobials in animal feed.  The 
task force report acknowledged that antimicrobial use, especially in sub-therapeutic doses, and 
the development of resistant bacteria in animals were associated.  On the basis of the task force 
report, the Code of Regulations (21 CFR 558.15) outlined the requirements for the sponsors to 
submit data demonstrating that the antimicrobial product intended for sub-therapeutic purposes 
did not lead to bacterial resistance [108]. 
In 1977, the FDA proposed to prohibit the in-feed, sub-therapeutic uses of tetracycline 
and penicillin due to concerns about the development of resistance.  These two drugs were 
widely used in human medicine at that time.  However, due to lack of sufficient epidemiological 
evidence, this action was never taken [108]. 
In 1987, the National Cattlemen’s Beef Association producer guidelines for ‘Judicious 
use of Antimicrobials’ were released.  These outlined the appropriate use of the available 
antimicrobials in animal agriculture [109].   
In 1997, the Center for Veterinary Medicine (FDA) for the first time prohibited the extra-
label use of fluoroquinolones and glycopeptides in the animal agriculture industry on the basis of 
the development of bacterial resistance as a sole cause for this legislation [110].  This order was 
released under the Animal Medicinal Drug Use Clarification Act (AMDUCA) which has been 
active since 1994.  The use of antimicrobial drugs like chloramphenicol, clenbuterol, 
diethylstilbesterol, dimetridazole, furazolidone, nitrofurazone, and sulfonamide drugs in lactating 
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dairy cattle (except approved uses) were prohibited earlier in animal agriculture.  However, these 
prohibitions were based on hazardous effects on human health because of the residues in animal 
products.  Drug residues could lead to direct exposure to the pharmaceutical compounds or their 
metabolites and pose public health risk [39]. 
In October 2003, the Center for Veterinary Medicine (FDA) released Guidance for 
Industry (GFI #152) as a regulatory tool consisting of guidelines to be considered in order to help 
prevent antimicrobial resistance in humans that may be a result of antimicrobial use in animals.  
The FDA recommended all new drugs intended to be used in food-producing animals undergo a 
qualitative risk assessment as a part of the pre-approval safety evaluation process, while applying 
for new drug approval.  The risk analysis process was based on the Office International des 
Epizooties (OIE) approach.  The three steps for the qualitative risk assessment of an animal drug 
involved release assessment, exposure assessment, and consequence assessment.  Release 
assessment was based on the probability that the target animal will develop resistant bacteria as a 
result of the drug use; exposure assessment involved the probability that humans will be exposed 
to those resistant bacteria through food; and consequence assessment was the probability that 
humans will face an adverse consequence because of the prior exposure to resistant bacteria.  
The overall risk estimate was classified into high, medium, and low.  The document also 
provided the list of antimicrobial drugs as classified into important, highly, or critically 
important categories.  This list was utilized in the consequence assessment component of the risk 
assessment [111]. 
In 2006, the Center for Veterinary Medicine (FDA) released Guidance for Industry 
(GFI#159) and then further revised it in March 2012.  This guidance highlights the effects of 
veterinary drug residues in food on human intestinal microflora.  The document provides 
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recommendations on (1) steps to determine if there is a need to establish a microbiological 
average daily intake (ADI) for particular antimicrobials used in animals; (2) test systems and 
methodologies for determining the concentration and levels of antimicrobials for microbiological 
endpoints; and (3) a procedure to derive microbiological ADI of antimicrobials in animals.  
Recommended microbiological endpoints to be considered are colonization barrier disruption 
leading to colonization of exogenous, possibly pathogenic bacteria and expansion of resistant 
bacteria in human gut.  The guidance recommended in vivo and in vitro tests to determine the 
threshold antimicrobial doses to be used in animals so that the residues do not adversely affect 
the ecology of human gut microflora using a harmonized approach [112]. 
In July 2008, the Center for Veterinary Medicine (FDA) issued a order of prohibition 
restricting the extra-label use of cephalosporin drugs in animal agriculture [113].  However, the 
rule could not be implemented immediately because of the large negative response from the 
animal health community.  The final prohibitory legislation for cephalosporins in animal 
agriculture came into place in April 2012 [7].  The order bans certain extra-label uses of 
cephalosporins such as biobullets in cattle, injection or dipping of poultry eggs, and self-
compounded preparations.  In essence, the use of cephalosporin drugs other than at approved 
dose levels, duration, frequency, and route of administration were prohibited.  This order was 
also released under the Animal Medicinal Drug Use Clarification Act (AMDUCA) that came 
into action in 1994. 
In April 2012, the Center for Veterinary Medicine (FDA) released Guidance for Industry 
(GFI#209).  This document recommended judicious use of the current medically important 
human drugs used in animal agriculture.  Uses of such drugs for growth promotion and feed 
efficiency were deemed to be injudicious.  The document provides the framework for voluntary 
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steps to be taken by the animal agricultural community in order to safeguard the efficacy of 
medically important drugs for human medicine.  The two principles outlined are (1) these 
medically important drugs should only be used in food-producing animals when it is deemed 
necessary for their health; and (2) the application of these drugs should be limited to purposes 
that mandate veterinary supervision or prescriptions [108]. 
The Preservation of Antibiotics for Medical treatment Act (PAMTA) is a proposed 
amendment to the Federal Food, Drug, and Cosmetic act that came into action in 1938.  PAMTA 
was reintroduced into congress in March 2013 after its previous introductions in March 2009 and 
2011.  The aim of this legislation is to protect the effectiveness of antimicrobials used in human 
and animal medicine by banning the non-therapeutic uses of medically important drugs in food-
animal production.  The 7 classes of antimicrobials included in the bill are penicillins, 
tetracyclines, macrolides, lincosamides, streptogramins, aminoglycosides, and sulfonamides.  If 
the bill is enacted, the non-therapeutic use of these 7 classes of antimicrobials will be banned 
unless drug companies can prove that human health is not impacted by their use.  It would also 
require the FDA to re-examine the approvals of antimicrobials used in animal agriculture [114].  
 
2.8.      Studies on ceftiofur and tetracycline resistance among enteric bacteria in cattle 
The effects of feeding chlortetracycline on antibiotic susceptibility among E. coli and 
Enterococcus was studied in 20 feedlot cattle in Texas [11].  Minimum inhibitory concentrations 
(MICs) against selected antimicrobials were determined by using a microbroth dilution 
technique.  The study results revealed that chlortetracycline treatment leads to a transient 
increase in the proportion of E. coli and Enterococcus resistant to tetracycline.  However, the 
same authors observed a drastic reduction in ceftiofur resistance among E. coli isolates while 
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chlortetracycline was being fed to the cattle.  Chlortetracycline differentially favored the E. coli 
isolates that were singly resistant to tetracycline over the ceftiofur and tetracycline co-resistant 
isolates.  These results suggested that chlortetracycline might minimize the proliferation and 
accumulation of ceftiofur resistant bacteria in production-animal agriculture settings.  The 
bacteria load was not quantified in the study.  Therefore, the increased proportion of tetracycline 
resistant isolates could be either due to a transitory increase in the resistant population due to 
antibiotic selective pressure or else to a decrease in the susceptible population that simply made 
the probability of detection of resistant isolates easier.   
The results from this study formed the basis of one of the hypothesis of the research 
project described in this thesis.  A total of 525 E. coli isolates were tested for susceptibility 
profiles. There were 397 isolates that exhibited resistance to atleast one antimicrobial. Out of 
those 397 isolates, 213 isolates were derived from the tetracycline treated group and 184 isolates 
were derived from the control group.  The proportions of isolates resistant to one or more 
antimicrobials in the treated and control groups were 81% and 70%, respectively.  The E. coli 
isolates from the control group were significantly less likely to possess resistance towards one or 
more antimicrobials as compared to the treated group (p=0.04).  However, the results from 
Enterococcus isolates revealed no significant differences in resistance proportions 
(approximately 90%) among both control the treated groups.  These results indicate that Gram 
negative and Gram positive bacteria may behave differently in terms of propagating 
antimicrobial resistances under similar antimicrobial selective pressure.  Therefore, drawing 
conclusion on the effects of antimicrobials on all bacterial populations based on a single or 
sentinel bacterial species may be misleading.  Other bacterial populations (culturable or non-
culturable) may act a reservoir or may behave differently under similar selective pressures.  
29 
 
 The effect of therapeutic doses of ceftiofur on E. coli diversity and changes in prevalence 
of blaCMY-2 genes among E. coli was studied in a single dairy farm in Illinois [115].  An 
observational study was conducted on 10 dairy cows, out of which 5 cows had been treated with 
ceftiofur for Leptospira borgpetersenii infection and 5 were matched untreated cows.  Total E. 
coli were enumerated as log colony forming units per gram sample.  A total of 468 E. coli 
isolates (203 and 265 isolates from treated animals and control group, respectively) were 
screened for antibiotic susceptibility testing against 16 antimicrobials using a microbroth dilution 
technique.  The blaCMY-2 gene was qualitatively detected using PCR assay from DNA derived 
from E. coli isolates as well as from the fecal community DNA.  The effect of ceftiofur treatment 
on genetic diversity among E. coli isolates was studied through repetitive element PCR (Rep-
PCR).  The total E. coli counts in the treated group were significantly lower as compared to the 
untreated group on 2 days during 5-day treatment period and 2 days post-treatment.  There was 
no significant increase in the quantity of resistant bacteria as measured by an antimicrobial 
resistance index, except for 3 days during treatment.  Susceptible bacterial population overtook 
the resistant fraction once the antibiotic selection pressure was removed.   
Overall, 6% of the 203 E. coli isolates in treated animals and none of the 265 isolates 
from untreated animals harbored the blaCMY-2 gene.  There was no horizontal cow-to-cow 
transmission from treated to the non-treated cows noticed during this phase even though the 
cows were allowed to co-mingle.  The probability of transmission of resistant bacteria was 
expected to be high since there was a significant decrease in the susceptible bacterial population 
in the treated group.  According to authors, the lack of detection of resistant strains could be 
because of small sample size, less sensitive test methodologies, or else ceftiofur-sensitive 
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bacteria in the non-treated animals were more fit than resistant strains and therefore the effect of 
exposure to resistant bacteria was not appreciable.  The probability of detecting transmission 
between treated and non-treated animals could have been increased by evaluating more isolates 
per animal, including using selective media for ceftiofur-resistant isolates to increase the assay 
sensitivity.  A cluster analysis of the antibiotic susceptibility profiles of E. coli isolates revealed 
that there were only two multidrug resistance clusters.  All E. coli isolates in these two clusters 
came from treated cows.  Importantly, the Rep-PCR results indicated that genetic diversity in E. 
coli population was indistinguishable between the treated and the control group, before 
treatment, during and after the treatment during the washout phase.  Therefore, the authors 
concluded that ceftiofur treatment did not cause either the emergence or amplification of 
ceftiofur resistant E. coli population.  However, considering the sample size there could be a 
possibility that in between group variation was not captured.  Also, caution should be taken to 
extrapolate these results to other bacterial genera that could behave differently upon ceftiofur 
treatment.   
Additionally, the emergence and amplification of resistance is a function of repeated 
usage over a long period of time.  Given the extensive usage of ceftiofur over decades in animal 
agriculture, it could significantly contribute to the emergence and amplification of ceftiofur 
resistant bacteria over time.  This may be evident by the NARMS data that indicate the increase 
in the baseline ceftiofur resistance among Salmonella isolates in cattle from 0% in 1998 to 14.5% 
in 2009 to 21.5% in 2010 (Figure 2.1).  The blaCMY-2 gene was detected in the community DNA 
from both treated as well as untreated cattle throughout the sampling days.  The authors 
concluded that resistant microbes or resistant determinants were present in the herd even prior to 
antibiotic treatment as revealed by the community DNA results.  Antibiotic treatment enhanced 
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the probability of detecting resistant isolates, primarily by decreasing the susceptible E. coli 
population.  Also, the authors rightly suggested that studying the effects of antibiotics on 
resistant culturable isolates alone is not sufficient to determine the true impact of antibiotic on 
entire gut microbiota.  The true strength and relationship of antibiotic use and antibiotic 
resistance among gut microbiota cannot be measured by evaluating the effect on one bacterial 
population like E. coli.  Quantifying particular target resistance genes in community DNA, 
derived from the entire gut microbiota, will be more useful to determine the true impact of 
antimicrobials on gut flora. 
 
A follow up study to Singer et al. (2008) [115] was conducted where absolute quantities 
of blaCMY-2 gene was measured by real time quantitative PCR from bacterial community DNA 
obtained from the previous study [8].  The mean blaCMY-2 gene copies in community DNA were 
significantly higher during the treatment phase in the ceftiofur-treated group as compared to the 
untreated animals.  There was also a small increase in the blaCMY-2 gene copy numbers among the 
non-treated animals.  The authors attributed this effect to co-mingling of treated and non-treated 
animals together.  The increase in the blaCMY-2 gene copies among the non-treated animals could 
be indicative of the horizontal transmission of bacteria among treated and non-treated co-
mingled cattle.  The results from this study suggested that the burden of resistance in terms of 
target resistance gene copies increased temporarily during the treatment phase.  Importantly, 
these findings were not evident with culture-based assay used in their previous study where the 
decrease in susceptible E. coli population was attributed to the ability to detect resistant bacteria 
rather than an actual increase in the population of the resistant population upon antibiotic 
treatment.  Overall, blaCMY-2 gene quantities ranged from a single copy to 41 copies per qPCR 
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reaction (per 5µl of sample community DNA).  There were 84% observations that were 
considered censored with either no Cq (cycle threshold) or genes less than 10 copies per qPCR 
reaction.  A hierarchical model was used to impute these censored observations.  The model was 
based on the number of censored observations among the sample triplicates used in the PCR 
assay.  Sixty one percent of the 129 fecal samples screened had at least one well among the 
triplicates which tested positive for the blaCMY-2 gene.  Among the 10 samples collected prior to 
ceftiofur treatment, there were 5 and 4 fecal samples that tested positive for blaCMY-2 gene from 
both treated and untreated groups, respectively.  The authors concluded that ceftiofur 
administration resulted in short term selection of blaCMY-2 gene.  They did not quantify the 
housekeeping gene for entire bacterial community like 16S rRNA gene.  Therefore, it is not 
possible to determine the impact of ceftiofur treatment on the susceptible population of bacteria, 
whether culturable or unculturable. 
 
The effect of three different doses or durations of ceftiofur (ceftiofur crystalline-free acid:  
CCFA) treatment was evaluated and compared on 61 steers in an experimental feedlot in Texas 
[116].  CCFA treated and non-treated steers were housed together in pens in the ratio of 1:1, 
where each pen housed 10 steers, except for one pen that had housed 11 steers.  This was done to 
mimic a real-life situation of feedlots in which treated and non-treated animals are allowed to co-
mingle.  A microbroth dilution technique was utilized to determine antimicrobial susceptibility 
towards 15 antimicrobials.  The three regimens of ceftiofur tested were single two-third dose 
regimen (4.4mg/kg administered once on day 0), single therapeutic dose regimen (6.6mg/kg 
administered once on day 0), and three consecutive therapeutic doses regimen (6.6mg/kg 
administered thrice on days 0, 6, 13).  The E. coli concentration was measured in terms of total 
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colony counts of non-type specific E. coli.  Approximately 68% of the 1,441 E. coli isolates 
possessed resistance to at least one out of the 15 antimicrobials tested.  Ceftiofur resistant 
isolates were found resistant to approximately 7 other antimicrobials.  Co-selection of resistance 
towards other antimicrobials was observed upon ceftiofur administration.  A perfect agreement 
was observed between ceftiofur resistance and the ACSSuT phenotype.  Also, there was a perfect 
agreement between ceftiofur resistance and reduced susceptibility towards ceftriaxone.  Ceftiofur 
administration led to transient increases in the population of ceftiofur-resistant isolates along 
with the reduction in total non-type-specific E. coli population.  The resistance levels returned to 
baseline values around 14 days post-treatment.  There was no statistical difference observed in 
the proportion of ceftiofur resistant isolates between the cohorts that received single dose of 
4.4mg/kg and 6.6mg/kg ceftiofur treatment.  Therefore, a causal ceftiofur dose effect (varying 
levels of antimicrobial selection pressure; e.g., sub-therapeutic verses therapeutic doses) on 
ceftiofur resistance was not evident from study results.   
The scientific literature and lay media tend to implicate antimicrobial resistance more to 
the sub-therapeutic administration of antimicrobials in food production animals.  However, 
duration of administration could be a confounding factor to such inferences.  Sub-therapeutic 
doses are usually given for longer duration of time for purposes described previously in this 
section.  The effect of co-mingling of treated and non-treated cattle was also not evident in this 
study.  The horizontal transmission of ceftiofur resistant bacteria among treated and non-treated 
cattle were not observed during the treatment phase.  The authors attributed this observation to 
the possibility of susceptible bacteria (harbored by non-treated animals) being more fit than 
resistant bacteria and therefore non-treated animals were not affected by exposure to resistant 
bacteria released into the environment by treated animals.  On the basis of this assumption, they 
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concluded that ceftiofur treatment may be a prerequisite to develop and disseminate ceftiofur 
resistance in E. coli.  This may not be entirely true.  Although fitness costs may be a valid 
explanation, assay sensitivity should also be considered.  The results were based entirely on 
phenotypic culture-based assay.  Culture-based assays may result in expulsion of resistance 
genes or the ingredients used in the agar may select for a subpopulation that may not possess 
those phenotypic characteristics.  The transmission probability as described earlier could have 
been increased by increasing the number of isolates tested per animal or by using selective media 
to select for ceftiofur resistant isolates [115].  
 
A follow up study to [116] was conducted where absolute quantities of blaCMY-2 gene and 
16S rRNA gene per gram of feces were measured by real time quantitative PCR assay [106].  
The quantification was performed on bacterial community DNA extracted from cattle feces.  The 
standardized (as ratio to log10 16S rRNA gene) log10 blaCMY-2 gene quantities for treatment 
groups receiving three doses of 6.6mg/kg and a single dose of one 4.4mg/kg both were 
significantly lower than the control group.  The decrease in standardized quantities on a log10 
scale (difference between the target gene copies and the house keeping gene) indicated either 
expansion of blaCMY-2 gene quantities, or concurrent reductions in the total bacterial population, 
or both among the total microbial fecal flora.  This led to lower standardized blaCMY-2 gene 
quantities in the two regimens described above.  The nonstandardized blaCMY-2 gene quantities 
(absolute quantities) for these two treatment groups were significantly higher than the control 
group.  The results suggested that different ceftiofur regimens in feedlot cattle may provide 
varied selection pressure.  This study also highlights the importance of reporting both absolute 
and standardized quantities that take into account the effect on the background population.  
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Although not explicitly mentioned, there was increase in the standardized blaCMY-2 gene copies 
over study days in the control group.  The least square means (lsmeans) log10 copies per gram ± 
standard error (SE) for standardized gene quantities of control group was 3.40 ± 0.34 and the 
baseline values for standardized blaCMY-2 gene quantities were approximately 2.6 log10 copies per 
gram.  This may indicate the effect of pen mates that underwent ceftiofur treatment on the 
untreated animals (co-mingling effect).  The impact of ceftiofur treatment on specific bacterial 
species could not be determined through this community DNA based assay. 
 
An observational study was conducted on 18 dairy herds in Ohio [117].  E. coli isolates 
from 1,266 fecal samples were screened to determine the association between the ceftiofur use 
and reduced ceftriaxone susceptibility.  E. coli with reduced susceptibility towards ceftriaxone 
were isolated from 12 out of these 18 herds.  Ten out of the 12 herds reported ceftiofur use.  A 
mean of 70 cows per herd was sampled.  The herds reporting ceftiofur use had 40% mean herd 
prevalence for reduced ceftriaxone susceptibility E. coli as compared to 9% in herds that did not 
report ceftiofur use.  The blaCMY-2 gene was identified in 355 of the isolates (83%) with reduced 
susceptibility to ceftriaxone.  Eighty one of these blaCMY-2 positive isolates representing each of 
the herds were tested for resistance towards 16 antimicrobials by a broth micro-dilution 
technique. All ceftiofur-resistant isolates were classified as resistant to 8 antimicrobials.  Herds 
reporting ceftiofur use were 25 times more likely to have cows from which reduced ceftriaxone-
susceptibility E. coli were isolated versus those that never used ceftiofur (p=0.01).  This was not 
true at the individual cow level within those herds that used ceftiofur (adjusted odds ratio=1.01; 
p=0.83).   
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There are several factors that could have influenced the study results.  The length of time 
between the recorded ceftiofur treatment and fecal sample collection was not controlled.  
Detailed antimicrobial usage data was recorded only for subset of dairy herds in the past 6 
months prior to sample collection.  Previous studies indicate that the probability of detecting 
ceftiofur resistant bacteria increases in the post ceftiofur treatment period.  However, this 
increase is found to be transitory and the resistance levels drop to baseline levels shortly after the 
selection pressure is removed [115-116].  The probability of finding a significant relationship 
between the ceftiofur treatment and resistant bacteria post antimicrobial washout phase seems 
low [116].  Also, this was a cross-sectional prevalence study so cause-effect relationship is hard 
to determine.  A convenient sampling of herd was performed.  This herd sample was studied 
despite having broadly similar management practices as other herds, but was not a true random 
representation of all dairy farms in Ohio or the United States.  The study was conducted in dairy 
cattle where only the short acting formulation was used.  Therefore, these results should not be 
extrapolated to beef cattle production systems where long acting formulations are more often 
being used.  One of the most important observations of the study was the significant herd level 
association of ceftiofur use and subsequent development of reduced susceptibility towards 
ceftriaxone.  This points to the treatment dependent ceftriaxone resistance baseline shift over 
time [116]. 
 
The effects of antimicrobial growth promoters on persistence and diversity of resistant E. 
coli in feces at both phenotypic and genotypic levels were studied in 90 steers [118].  A control 
group (no antibiotic exposure) and two cattle groups administered tetracycline based 
antimicrobial growth promoters (chlortetracycline alone or chlortetracycline and sulfamethazine) 
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were involved in the study.  Fecal deposits were prepared subsequent to the group treatments 
which were administered to steers form arrival day of feedlot to 197 days.  Fecal deposits were 
sampled 12 times over 175 days and examined for proportions of ampicillin and tetracycline-
resistant E. coli.  E. coli were isolated using plain MacConkey agar or else MacConkey agar 
supplemented with ampicillin or tetracycline at breakpoint concentrations according to CLSI.  
The resistant E. coli were screened for the genotypic diversity through pulse field gel 
electrophoresis and were subjected to PCR assay for detection of various genes coding for 
tetracycline, ampicillin, and sulfonamide resistances.  The generic E. coli CFU counts were 
found to be similar among the three study groups.  Numbers of tetracycline-resistant E. coli were 
higher in the groups fed chlortetracycline as compared to the control group.  High numbers of 
tetracycline resistant bacteria (more than 5 log10 CFU/gram of dry matter in both treated groups) 
were found even after the fecal deposits were exposed to environment for 175 days, post-
treatment.  High numbers of tetracycline-resistant bacteria were observed even on day 0 in the 
control group.  Results of this study suggest that tetracycline resistant bacteria can survive for 
long durations in environment.  Also, the baseline tetracycline resistance is relatively high 
(Figure 2.1), likely due to tetracycline usage over many decades.  This suggests that harboring 
tetracycline resistant determinants imparts minimal fitness cost to the bacteria even in the 
absence of selective pressures.   
The cattle themselves may have acquired these resistant bacteria from environmental 
sources.  The number of E. coli, except ampicillin-resistant E. coli, increased in the fecal deposits 
up to day 56 (p<0.001).  The authors attributed a decrease in ampicillin resistant E. coli 
population to selective pressure of growth promoters in the ruminant gut that selected for the 
population that could not survive as well as the resistant population that did not have antibiotic 
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exposure.  These results suggest persistence of resistant bacteria in fecal deposits for extended 
durations.  It makes these deposits a significant source of these bacteria that may spread in 
environment via various channels like water and thereafter pose a public health risk.  Factors 
listed that influenced bacterial persistence included: moisture content, external temperature, 
ability of oxygen to penetrate fecal deposits, chlortetracycline degradation time, and nutrient 
availability.  Both antimicrobial growth promoter and the sampling time influenced the E. coli 
genotypes as determined by PFGE.   
This study demonstrated the phenomenon of differential selection of resistance genes 
depending on the usage of antimicrobial growth promoter.  The majority of the ampicillin 
resistant E. coli that harbored a tet(A) gene came from the chlortetracycline group and the ones 
that harbored tet(B) came from the chlortetracycline and sulfamethazine group.  These results 
indicate the possible association of tet(A) gene with chlortetracyline when administered alone.  
The most prevalent tetracycline resistant determinant reported among tetracycline resistant 
isolates was tet(B).  The between animal variation could not be reported as the samples per 
treatment were pooled. 
 
The effect of ceftiofur on the selection and dissemination of the blaCMY-2 gene was 
studied in cattle, both through in vivo conjugation experiments and a multiple herd based field 
study [119].  The two donor (E. coli) and six recipient (four E. coli and two Salmonella) strains 
were utilized in the in vivo experiment after determining their capability to exchange plasmids 
through prior in vitro experiments.  Glycerol stocks for both donor and recipients were prepared 
for oral inoculation.  The in vivo experiment involved 10 calves aged 3-4 months.  They were 
randomly allocated to treatment and control groups.  The study was divided into 3 phases: 
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pretreatment phase (Day -7 to -1), treatment phase (Day 0 to 8), and post treatment phase (Days 
9 to 14).  A single dose of ceftiofur treatment was given at day -7 to increase the probability of 
detecting ceftiofur resistant populations that could behave as donors during the experiment.  
Ceftiofur was administered at dose rate of 2.2 mg/kg body weight from day 2 through 6.  Oral 
inoculums consisting of recipient strains and donor strains were given alternately from day 0 
through day 13.  Selective and non-selective agars were utilized to enumerate the total E. coli 
load as well as donor and transconjugant ceftiofur resistant colonies.  The transconjugants were 
confirmed using molecular methods.  No donor, recipients, or transconjugants were detected, 
during the pretreatment phase.  The donor and recipients were detected and constituted 
substantial proportions of the total E. coli numbers in both groups during the entire course of 
treatment and post treatment phases.  The E. coli populations were found to decrease during the 
ceftiofur treatment in the treated group.  Salmonella isolates were detected in all calves on some 
experimental days but the recipient strains formed a small proportion of total lactose fermenting 
CFU’s.  Three calves in each group possessed transconjugants in their fecal samples showing the 
horizontal plasmid transfer in the animal gut.  However, the ceftiofur treatment was not found to 
increase the probability of detection of transconjugants as hypothesized.  There were just 5 
calves in each group.  The sample size does not seem enough to capture the variability in 
between the two groups and demonstrate statistic differences in between the two groups.  The 
standard errors were large.  The inferences were based on single trial on 10 animals. Most 
importantly, the ceftiofur treatment clearly reduced the E. coli populations during the ceftiofur 
treatment phase.  This was the phase where authors expected to find increased proportion of 
transconjugants.  Ceftiofur killed the sensitive bacteria that were supposed to act as the 
recipients.  Therefore, the reduced presence of recipient E. coli likely adversely affected the 
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transconjugation process as seen from these results.  The value of relative proportions of donor 
and recipient strains (to the total fecal coliform) drop to zero on a log10 scale on several 
occasions in both groups during the course of the study.  This indicated the lack of either donor 
or recipient strain expected to participate in transconjugation process, at those time points.  
Moreover, the administration of donor and recipient strains were alternated over days both 
during and after ceftiofur-treatment phase.  This was done to reduce the probability of 
conjugation process to begin in the mouths of the calves.  The alternate administration of strains 
might have affected the transconjugation process.  The successful conjugation process requires 
sufficient quantities of both donor and recipients strains.  It was found that the fecal flora was 
predominated by the strains (donor or recipients) that were administered on the previous day.   
Therefore, the donor and the recipient may not be adequate proportion at the same time point in 
the animal gut.  Study results may also be affected by the donor and recipient strains used.  The 
donor strains were obtained from calves and the recipient strains were obtained from cows.  The 
experiment was performed in calves and therefore the cow adapted recipient strains may not be 
able to adapt well to calf gut environment.   
The herd level component of the study was conducted on 42 dairy herds in the state of 
Washington.  Twenty eight pooled fecal samples from each herd were collected from 2006 to 
2007.  Each pooled samples was a composite of 10 individual fecal samples.  Herd records were 
checked for past cases of ceftiofur resistant clinical Salmonella from 2003 to 2007.  Purchase 
records of ceftiofur formulations as well as ceftiofur use within the herd were recorded.  The 
herd level pooled fecal samples were subjected to E. coli enumeration and detection of 
Salmonella isolates.  Antimicrobial susceptibility testing was performed using the agar diffusion 
technique in E. coli and the microbroth dilution technique in Salmonella.  The blaCMY-2 gene was 
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detected among the isolates.  The herd level study also did not identify any association of the 
magnitude of ceftiofur usage in the herd and frequency of ceftiofur resistant E. coli.  This led the 
authors to conclude that ceftiofur use does not play an important role in the persistence and 
dissemination of ceftiofur resistant commensal E. coli.  However, as shown in Tragesser et al. 
(2006) [117], the within herd effects are much more difficult to identify than between herd 
(use/no use) effects.  The usage of other antimicrobial drugs used during the dairy farm 
operations may have confounded the results.  The short acting formulation of ceftiofur is often 
used in dairy farms; therefore, the results cannot readily be extrapolated to beef cattle systems 
where longer acting formulations usually are used.   
 
A longitudinal study was conducted at the U.S. Meat Animal Research Center, Clay 
Center, Nebraska feedlot on 763 cattle [120].  Ceftiofur was the drug of choice for therapeutic 
purposes in this feedlot.  Animals were monitored longitudinally for 10 months and fecal 
samples were collected during 6 sampling periods.  Antimicrobial growth promoters were not 
administered to the animals.  The authors studied the fecal and hide prevalence’s of extended 
spectrum cephalosporin resistant E. coli (ESCREC) among the cattle, during their stay.  This 
included the cattle that received therapeutic ceftiofur treatment.  A total of 312 isolates was 
found to be ESCREC and these were characterized using pulsed field gel electrophoresis, 
antibiotic susceptibility testing, plasmid size analysis, qualitative detection of blaCMY-2 gene, and 
plasmid replicon typing for 18 plasmid incompatibility groups.  The authors reported that 
therapeutic ceftiofur use did not significantly increase the ESCREC prevalence at the herd level.  
However, a significant increase was observed in ceftiofur-resistant E. coli shedding following the 
ceftiofur use.  The authors only presented the absolute ESCREC CFU counts over the study 
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period.  They did measure the total lactose-fermenting coliforms in both fecal and hide samples 
and indicated that the proportion of the ESCREC on the feces and hide samples were 
significantly lowered as compared to the total lactose-fermenting coliforms.  However, the 
relative counts over the study period were not presented.  Therefore inferences regarding the 
effect of ceftiofur administration on the background susceptible population cannot be made and 
this may have biased the results.   
The baseline fecal ESCREC prevalence upon cattle arrival was reported to be 3.9%.  
Subsequently, the herd prevalence was found to be in the range of 1.7 to 11.2%; these 
prevalences were not statistically higher than the ESCREC baseline prevalence on arrival.  The 
hide prevalence of ESCREC was 15% on arrival.  This prevalence also did not significantly differ 
during most of the study.  All 312 ESCREC isolates harbored the blaCMY-2 gene.  The study 
results indicate a clear association between ceftiofur resistance and the blaCMY-2 gene.  The 
persistence of blaCMY-2 gene was contributed to clonal expansion as opposed to the horizontal 
transfer of the gene.  This was evident by the low diversity of PFGE results that revealed only 26 
unique patterns, 12 of which were identified from the samples collected during multiple 
sampling periods.  All 312 ESCREC isolates were found to be resistant to at least 3 other 
antimicrobials.  The most common phenotype observed in 99.7% of ESCREC isolates included 
resistance to nine other antimicrobials.  The plasmid replicon typing results revealed that IncA/C 
replicon was the most prevalent replicon (69.2%) followed by IncY replicon, among the 18 
plasmid replicons they tested.  The authors concluded that ceftiofur use on this farm may not be 
the most significant source of ceftiofur resistant organisms that would be present in the final 
meat products that pose a risk to human health. 
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2.9.  Summary of literature review 
There has been an increase in antimicrobial usage over the years, used to promote and to 
sustain animal agriculture in the United States.  The usage of critically important drugs like 
ceftiofur in animal agriculture has resulted in a public health concern due to the possible transfer 
of resistant strains or gene determinants to humans.  The percentages of ceftiofur and tetracycline 
resistant cattle isolates in NARMS have been found to increase over the past 15 years.  The 
important determinants for ceftiofur resistance are the genes coding for β-lactamases like blaCMY-
2 and blaCTX-M.  In the United States, blaCMY-2 is mostly associated with ceftiofur resistance in 
animals.  The blaCTX-M is more prevalent in Europe and is rarely reported in the United States.  
The most common tetracycline resistance determinants in cattle are tet(A), tet(B), and tet(C).  
Most studies investigating the effect of ceftiofur and tetracycline conclude that the antimicrobial 
treatment only aids in transitory increase in the resistance levels and the levels returns to the 
baseline once the effect the selective pressure effect is removed.  However, the temporal and 
aggregated scale upon which these baselines are observed makes it difficult to observe and trace 
their steady increase over the decades.   
There have been several observational studies evaluating the association of ceftiofur or 
tetracycline use in farms and the corresponding levels of the resistance and associated multidrug 
resistances.  Most studies base their finding on phenotypic and genotypic culture-based assays 
focusing on evaluating antimicrobial effects on a single or few sentinel organisms.  More 
recently, metagenome-based approaches are being used; these utilize community DNA to 
evaluate the effect of antimicrobials on the entire microbial community rather than just a few 
bacterial species.   
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Regulatory bodies like FDA have passed new guidelines and rules for restricting the 
usage of antimicrobials, especially the critically important antimicrobials, in food-producing 
animals to ensure human health.  It is critical to better understand those factors that could 
influence resistance dynamics in terms of development, propagation, and persistence of 
antimicrobial resistance determinants among enteric bacteria. This understanding is imperative 
for being able to design and test treatment strategies at the farm levels in order to control this 
global problem.  This study is aimed at evaluating the effects of two treatment strategies on 
ceftiofur and tetracycline resistance using both culture-based and metagenome-based approaches.  
Understanding the associations between the treatment and the resistant determinants and also the 
association among the various determinants is important for designing interventions strategies to 
control the problem of antimicrobial resistance. 
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 Chapter 3 
Quantitative analysis of bacterial resistance elements in the bovine 
fecal metagenome: chlortetracycline use rapidly expands 
cephalosporin resistance elements in a randomized controlled trial 
 
3.1.       Abstract 
The objective of this study was to determine the effects of two treatment regimens on the 
quantities of ceftiofur and tetracycline resistance genes in feedlot cattle.  The two regimens 
consisted of ceftiofur crystalline-free acid administration (CCFA) at either one or all the steers 
within a pen, and subsequent feeding/not feeding of therapeutic doses of chlortetracycline.  In a 
26 day randomized controlled field trial, 176 steers were allocated to 16 pens of 11 steers each.  
The two treatment strategies were randomly assigned to the pens in a two-way full factorial 
manner resulting in four treatment groups.  Quantitative real-time PCR was used to quantify 
blaCMY-2, blaCTX-M, tet(A), tet(B), and 16S rRNA gene copies per gram of feces from fecal 
community DNA.  Pens in which all the steers received the CCFA treatment showed an increase 
in ceftiofur resistance in terms of blaCMY-2 and blaCTX-M log10 gene copies per gram wet feces; 
this was in contrast to the pens where CCFA was administered to one steer among 11 pen mates.  
There was a significant decrease in both tetracycline resistance genes in those pens in which all 
animals received CCFA treatment.  Thereafter, chlortetracycline administration led to rapid 
expansion of both ceftiofur (blaCMY-2, blaCTX-M) and tetracycline [tet(A) and tet(B)] log10 gene 
copies per gram of feces.  Chlortetracycline administration did not lead to a hypothesized 
decrease in ceftiofur resistance determinants in feedlot cattle; in fact, our data suggest that 
46 
 
chlortetracycline use is contraindicated when attempting to avoid expansion of resistance to the 
critically important 3rd generation cephalosporins.  
 
3.2.       Introduction 
Cephalosporins are used in both animals and humans to treat a wide variety of bacterial 
diseases.  Cephalosporins sold or distributed in the United States for use in food-producing 
animals for the year 2011 amounted to 26,611kgs [23].  Ceftiofur, a third generation 
cephalosporin, is used in beef cattle to treat bovine respiratory disease and acute bovine 
interdigital necrobacillosis [121].  Ceftiofur is classified as a critically important antibiotic by the 
World Health Organization (WHO) [5].  It belongs to the same general class of antibiotics as 
ceftriaxone, which has been highly valued in human medicine for treating serious and life 
threatening infections.  Ceftriaxone is one of the few drugs accepted for use in children for 
treating invasive salmonellosis [122-123].  Emergence and spread of Salmonella resistant to 3rd 
generation cephalosporins among humans have been linked by some authors to ceftiofur use in 
veterinary practice [76, 106, 124-126].  Data from the 2010 U.S. National Antibiotic Resistance 
Monitoring System (NARMS) indicate that 2.8% of the non-Typhi Salmonella isolates arising 
from human clinical cases were resistant to both ceftiofur and ceftriaxone.  At the same time, 
21.5% of the non-Typhi Salmonella isolates, obtained from food-producing animals at slaughter, 
were resistant to both ceftiofur and ceftiaxone.  This is a significant increase in comparison to the 
14.5% of the non-Typhi Salmonella animal isolates that were resistant in 2009.  The prevalence 
of ceftriaxone resistance among human isolates has been observed to be relatively stable since 
2004; however, in 2010 ceftriaxone resistance among non-Typhi Salmonella cattle isolates 
(22%) was observed to be at its highest since NARMS testing began in 1997 [107].  In response 
to the observed increases in cephalosporin resistance among food animal non-Typhi Salmonella 
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isolates and to preserve antibiotic efficacy in both veterinary and human medicine, in April 2012 
the U.S. Food and Drug Administration released an order restricting certain extra-label uses of 
cephalosporin drugs in food-producing animals [127].  
Restricting or banning the use of some antimicrobial classes in animal agriculture may result in 
unintended consequences, such as an increase in therapeutic use of antimicrobials that may be 
critical for human medicine [20, 128].  There is a need to design and test intervention strategies 
to control ceftiofur resistance at the farm level in order to protect both animal and human health.  
Studies in human medicine have demonstrated a protective effect of fluoroquinolone use as an 
alternative intervention against the emergence of cephalosporin resistance [129-130].  Our 
previous work suggested that chlortetracycline in feed significantly decreased the prevalence of 
ceftiofur resistant E. coli [11].  The outcome measure in that study was strictly phenotypic 
utilizing a culture-based approaches; that is, the proportion of bacteria resistant to a panel of 
antimicrobials (NARMS CMV1AGNF Gram negative panel, Trek Diagnostics, Cleveland, OH).  
Further, the total bacterial load was not quantified so the effect of chlortetracycline on the 
background population could not be determined.  This current study aims to evaluate the effects 
of chlortetracycline on ceftiofur and tetracycline resistance gene copies and also the 16S rRNA 
gene copies using quantitative RT-PCR assay, in the fecal metagenome.  Relying strictly on 
phenotypic, or even genotypic, data from cultured isolates restricts the focus to a very small 
subset of the gut microbiome.  Rarely are resistance elements restricted to one genus (e.g., 
Escherichia or Salmonella) or even family (e.g., Enterobacteriaceae).  If results from our 
previous work [11] prove to be robust across the entire metagenome, chlortetracycline might be 
expected to minimize the proliferation and accumulation of ceftiofur resistant bacteria and their 
resistance elements in production-animal agriculture settings.  Overall, in the present study, 
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samples were evaluated both at phenotypic [131] and genotypic levels; the latter involving both 
analysis of fecal bacterial isolates [131-133] as well as the broader metagenome.  This chapter 
focuses on the results obtained from the analysis of resistance genes present in the metagenome.  
This quantitative study further explores the differential selection and co-selection of the 
resistance genes based in fecal metagenome, upon antimicrobial treatments.  Several studies 
including this study on E. coli isolates demonstrated the phenomenon of differential selection of 
resistance genes based on chlortetracycline exposure [118, 131-132].  Other studies have 
likewise reported associations among various tetracycline and ceftiofur resistance genes [42-43, 
64, 134].  
Although not universally accepted, many scientists believe that resistance genes are 
associated with a fitness cost to the host, at least initially after the introduction of the drug in the 
market for clinical practice [9-10, 135-136].  The animals within a pen are suggested to exchange 
bacterial strains/resistant determinants (horizontal transmission) among each other [8].  The un-
treated animals may become a source of antimicrobial susceptible bacterial strains to the treated 
animal harboring resistant bacteria/determinants in the pen.  It has been proposed that readily 
available susceptible bacteria may help to promote the rapid re-colonization of the animal gut, 
helping to outcompete the resistant bacteria [137]. 
The primary objective of this study was to investigate the effects of two treatment strategies, 
i.e., 1) the ratio of housing of CCFA-treated with untreated animals on the levels of ceftiofur and 
tetracycline resistance genes copies in the fecal metagenome and, 2) the feeding of therapeutic 
doses of chlortetracycline following treatment with ceftiofur crystalline-free acid (CCFA). 
Quantitative real time PCR was performed on fecal community DNA to determine the changes in 
microbial populations as measured by variations in target gene copies [blaCMY-2, blaCTX-M, tet(A), 
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tet(B), and 16S rRNA genes] under the influence of various treatments.  The study results are 
essentially quantitative; that is, the results are expressed in terms of both absolute resistance 
genes copies or standardized to the 16S rRNA gene copies representing the total bacterial 
population.  Our primary hypothesis was that both strategies would help to decrease the levels of 
ceftiofur resistance elements in the fecal metagenome. 
 
3.3.       Materials and Methods 
Study design  
Bovine fecal samples were obtained from feeder cattle in a 26-day field trial.  The 
randomized controlled longitudinal study was conducted on 176 steers housed in two replicates 
of 88 steers each.  For each replicate, steers were assigned to 8 pens of 11 steers such that the 
average pen weights were similar.  A total of four treatment groups resulted from the random 
allocation of two intervention strategies in a complete two-way full factorial manner.  The two 
intervention strategies were: 1) differential pen-level CCFA treatment ratios (Mix) and, 2) 
subsequent pen-level chlortetracycline treatment (CTC). Pen-level CCFA treatment ratios (Mix) 
referred to whether long acting CCFA (Excede®, Zoetis Animal Health, NJ, U.S.A.) was 
administered to either one or else all 11animals within pens and pen-level CTC treatment 
referred to whether all cattle in a pen received chlortetracycline treatment top-dressed in feed 
subsequent to the CCFA treatment, respectively.  The study day (Day) was considered as the 
third factor in the statistical models.  This accounted for the effect of day of trial on the quantities 
of resistance genes detected in feces from the steers. 
A single dose of CCFA treatment (Excede®, Zoetis Animal Health, NJ, U.S.A.) was 
injected subcutaneously in all steers in 8 of the 16 pens at a dose rate of 6.6 mg/kg, on Day 0.  
Subsequently at the base of the ear, 4 of these 8 pens received chlortetracycline treatment at the 
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labeled dose rate of 22mg/kg body weight (Aureomycin®, chlortracycline complex equivalent to 
220.5g of chlortetracycline/kg, Alpharma, Bridgewater, NJ).  Chlortetracycline was administered 
during three separate 5-day periods (with a one-day break in between).  It was top-dressed after 
the morning feed was delivered, according to the label directions starting at Day 4.  In the 
remaining 8 pens, one steer among 11 pen-mates within the pen received CCFA treatment.  
Subsequent chlortetracycline treatment among these 8 pens was likewise given to all animals in 
just 4 of the pens (Table 3-1).  All allocations of animals to pens, pens to treatments, and 
treatments to animals within pen (where indicated; differentially CCFA treated pens) were via 
randomization protocols. 
 
Sample collection and qPCR methods 
Fecal grab samples were collected per rectum every other day from Day 0 to Day 26, after 
restraining the animals in a squeeze chute.  A new obstetric sleeve was used to collect fecal 
sample from each animal.  All samples were transported on ice to the laboratory on the day of 
sample collection.  A total of 2,424 samples were collected.  Five milliliter vials were filled to 
the 4 ml level with fresh feces.  These fecal samples were stored at -70°C for further genotypic 
analysis.  
 
Community DNA Extraction 
Total community DNA was extracted from 200mg feces via the QIAamp DNA Stool Mini Kit 
TM (Qiagen, Valencia, CA) according to manufacturer’s instructions.  The extraction was 
performed in the QIAcube robot TM (Qiagen, Valencia, CA).  The quality and concentration of 
DNA samples were determined via NanoDrop® ND-1000 UV-Vis Spectrophotometer 
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(NanoDrop Technologies, Wilmington, DE).  The DNA concentration in ng/µl was recorded. 
These DNA samples were used for further genotypic quantification.  
 
Genotypic quantification of target genes in community DNA 
Gene copies/g wet feces of blaCMY-2, blaCTX-M, tet(A), tet(B), and 16S rRNA genes were 
determined in fecal community DNA using quantitative real time PCR (qPCR).  All 4 resistance 
gene copies were standardized to the 16S rRNA gene, used as the reference gene in this study.  
The PCR plates were set up using an automated robot (QIAgilityTM, Qiagen, Valencia, CA).  The 
fecal community DNA was used directly as a template in qPCR reactions for quantification of 
the genes using a Stratagene Mx3005PTM real-time qPCR system (Agilent Technologies, La 
Jolla, CA).  The real time qPCR reactions for blaCMY-2 and 16S rRNA genes were adapted from a 
technique previously described [106]; qPCR reactions for tet(A), and tet(B) genes were adapted 
from [138]; and qPCR reactions for blaCTX-M  were adapted from [133].  All 2,424 samples were 
quantified for blaCMY-2 and 16S rRNA genes per gram; however, only samples from Days 0, 4, 
12, and 26 were chosen for tet(A), tet(B), and blaCTX-M gene quantification.  All community 
DNA qRT-PCR assays were run in triplicate. 
 
Primers 
Nested PCR was used to quantify two of the target genes.  Broad range primer sets (585F and 
1038R) and (1056F and 1456R) for blaCMY-2 and 16S rRNA genes, respectively, were used to 
obtain the PCR products.  These PCR products were used further as template for the standard 
curves in the nested runs.  The second primer sets (675F and 738R) for blaCMY-2 and (P201 and 
P1370) for 16S rRNA genes, respectively, were used in the nested amplification to determine the 
target gene copies in the unknown samples.  A single pair of primers specific for each of tet(A), 
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tet(B), and blaCTX-M genes were used for both PCR template generation as well as the 
quantification of the unknown samples.  Primers set details are listed in Table 3-2. 
 
Controls  
Negative control: Two negative controls were run with each PCR plate.  One was the no-
template control and the other had water as a template. 
Positive Control: E. coli strain (M1) was used as the positive control for the blaCMY-2 and 
16S rRNA gene.  It was obtained from the University of Illinois, Chicago [139].  XL1-Blue E. 
coli strain (Agilent Technologies, Santa Clara, CA) and E. coli ATCC 47042 were used as the 
positive controls for tet(A) and tet(B) genes, respectively.  The blaCTX-M positive control was an 
E. coli isolate internal control strain obtained from this study, which was positive on PCR with 
the specific primers.  The PCR product from this strain was sequenced for confirmation of the 
blaCTX-M-32 gene and has been published elsewhere [133].  The positive control strains were 
plated on blood agar (Thermo Fisher Scientific, Lenexa, KS) and were incubated at 37°C for 18 
hours.  DNA isolation was carried out by suspending a colony in 500µl of nuclease free water 
(Qiagen, Valencia, CA) and then by heating the suspension at 95°C for 10 minutes and storing at 
-20°C.  One positive and two negative controls were run with each plate.  These controls were 
also used for the generation of template for the standard curve in the 1st amplification reaction. 
 
Template for the standard curve generation- 1st amplification reaction 
Real time qPCR reactions were performed with broad range primers for 2 genes (blaCMY-2 
and 16S rRNA) in a total volume of 22µl.  Each reaction contained 12.5µl of 2×Brilliant II 
SYBR® Green QPCR Master Mix (Agilent Technologies, Santa Clara, CA), 4.75µl of nuclease 
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free water (Qiagen, Valencia, CA), 1µl of each primer, 0.75µl of reference dye, and 2µl of the 
DNA extracted from M1 strain (positive control).  For the blaCMY-2 gene, the thermal profile for 
amplification was 95°C for 10 minutes, 35 cycles of 95°C for 10seconds, 55°C for 45 seconds, 
and 84°C for 20 seconds.  Similarly, for the 16S rRNA gene, the thermal profile for 
amplification was 95°C for 10 minutes, 35 cycles of 95°C for 30seconds, 60°C for 1minute, and 
72°C for 30seconds.  Both tet(A) and tet(B) gene quantification reactions were run in a total 
volume of 20µl.  Each reaction contained 10µl of 2×Brilliant II SYBR® Green QPCR Master 
Mix, 6.25µl of nuclease free water, 0.5µl of each primer, 0.75µl of reference dye, and 2µl of the 
positive control DNA [XL1-Blue E. coli strain-tet(A) and E. coli ATCC 47042-tet(B)].  The 
thermal profile for amplification for both tet genes was 95°C for 10 minutes, 45 cycles of 95°C 
for 15 seconds, 60°C for 30 seconds, and 72°C for 28 seconds.  The blaCTX-M gene quantification 
reactions were run in a total volume of 25µl.  Each reaction contained 12.5µl of 2×Brilliant 
SYBR® Green II QPCR Master Mix, 9.5µl of nuclease free water, 0.625µl of each primer, 0.75µl 
of reference dye, and 1µl of the positive control DNA.  The thermal profile of these reactions 
was 94°C for 5 minutes, 40 cycles of 94°C for 1 minute, 57°C for 1 minute, and 72°C for 1 
minute.  Thermal profiles for all genes targets ended with one last single cycle to obtain a 
dissociation curve, which consisted of 95°C for 1 minute, 55°C for 30 seconds, and 95°C for 30 
seconds.  All real time PCR reactions were carried in the Mx3005PTM (Agilent Technologies, 
Santa Clara, CA). 
The PCR products were purified using a DNA purification Kit (Promega Corporation, 
Madison, WI).  This purified DNA was used as the template for generating standard curves, after 
determining its concentration via NanoDrop® ND-1000 UV-Vis Spectrophotometer (NanoDrop 
Technologies, Wilmington, DE) at wavelengths of 260 and 280nm.  The quantities of target gene 
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copies µl-1 for standard curve generation were determined under consideration of the molecular 
weight of the amplicons, weight of one mole of base pairs, and concentration of PCR product.  
Standard curves used the 10 fold serial dilution of the 2µl purified PCR products (with known 
number of gene copies) to 18µl of nuclease-free water to a minimum concentration of 100 for 
blaCMY-2, both tetracycline genes, and blaCTX-M and a minimum concentration of 103 for 16S 
rRNA gene.  The lowest five concentrations were used to build each standard curve. The 
standard curve was run in triplicate for every plate. 
 
Quantification of target genes in unknown samples-2nd amplification reaction   
Narrow range primers for blaCMY-2 and 16S rRNA genes and the same set of 1st 
amplification reaction primers for the tet(A), tet(B), and blaCTX-M resistance genes were used to 
quantify the gene copies in the unknown samples along with the standard curve.  All reactions, 
including standards, were run in triplicate in a total volume of 22µl for blaCMY-2 and 16S rRNA 
genes, 20µl for tet genes, and 25 µl for the blaCTX-M gene.  The reaction mixture composition was 
same as that of the 1st amplification reaction for all respective genes.  The thermal profile for 
amplification in the Stratagene Mx3005PTM system (Agilent Technologies, Santa Clara, CA) for 
the blaCMY-2 gene was 95°C for 10 minutes, 40 cycles of 95°C for 10 seconds, 52°C for 30 
seconds, and 79°C for 17 seconds.  Likewise, the thermal profile for the16S rRNA gene was 
94°C for 10 minutes, 40 cycles of 94°C for 2 minutes, 60°C for 1 minute, and 72°C for 17 
seconds.  Thermal profiles for the tet(A) and tet(B) and blaCTX-M resistance genes were the same 
as for the 1st amplification reaction.  Dissociation curves were run with every plate to examine 
the specificity of the amplifications.  Sequencing of PCR products was carried out on an ongoing 
basis for a random subset of reaction runs to further confirm the specificity of the products. 
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Comparisons against published online Basic Local Alignment Search Tool database at the 
National Center for Biotechnology were conducted. 
 
Statistical Analysis: 
 The gene copy number estimates were derived from either 1or 2 μl of the sample 
community DNA depending on the gene being quantified.  The gene quantities per microliter 
were back calculated to gene copies per gram wet feces.  The factor determined for back 
calculation to gene copies per gram of wet feces was 7,000 or 3,500 depending on whether 1 or 2 
µl community DNA template was used in final assay.  Community DNA was extracted from 
200mg feces (one gram fecal sample would be expected to have 5 times greater gene quantities).  
The DNA extraction process had a total calculated DNA loss by a factor of 7.  The final DNA 
suspension obtained was 200 µl.  Only 1-2µl DNA was used in the final assay depending on the 
gene quantified; therefore, the final volume used was expected to have 200 (or 100) times less 
DNA as compared to the 200 µl final volume.  The final factor was the product of all the factors 
(5, 7, 100 (or 200)) constituting the total loss of DNA during the process.  Non-standardized 
blaCMY-2, blaCTX-M, tet(A), and tet(B)  gene copies per gram wet feces and the quantities obtained 
by standardizing them in a ratio with the 16S rRNA gene were used for the outcomes.  All 
standardized and non-standardized quantities were logarithmically transformed to log base 10 for 
use as a dependent variable in both imputation and linear mixed models.  
A missing value was recorded in instances where qPCR amplification was below the 
quantification limit of the assay or else was below the threshold limit determined by the assay.  
These observations were considered missing.  These observations were assumed to have values 
more than zero but below the limit of quantification of the assay utilized.  Estimates of missing 
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values were imputed using multiple imputation procedures in STATA® SE Release 12.1 
(STATA Corp., College Station, TX).  This is a simulation-based method to handle the missing 
values.  Several plausible imputed datasets are created in this procedure and results from each are 
combined by taking the average over the distribution of these missing data.  This permits 
accounting for the uncertainty linked with the missing data [140].  These imputed datasets for 
missing values were sampled from a predictive distribution which was based on the observed 
data.  Therefore, this procedure is based on a Bayesian approach [140].  A multiple regression 
method was utilized for the imputation process.  Importantly, multiple imputation procedures 
utilize the known covariates that are believed to be associated with the missing values [141].  
Our imputation model was based on the unique animal id (repeats within animal), sampling day, 
and the number of observations missing among the triplicate for each sample (i.e., 1, 2 or all 3 
triplicates were missing).  Twenty imputations were performed to reduce the sampling variability 
from the imputation process [142].  The descriptive statistics of several imputed datasets (out of 
20 datasets) were compared to the non-imputed dataset and also results of the main linear 
regression models before and after imputation were compared to rule out any bias that might 
introduced during the imputation procedure. 
To determine the effect of treatment on gene quantities, a multi-level mixed linear model 
was utilized on the datasets following imputation.  The three explanatory variables tested in the 
model were pen-level CCFA treatment (ratio at which CCFA was administered within a pen), 
pen-level CTC administration, and the sampling days (period).  The relationships among the 
outcome and the explanatory variables were assessed using the mixed linear regression model 
with three-way full factorial design of the three explanatory variables (fixed effects) in STATA® 
SE Release 12.1 (STATA Corp., College Station, TX).  The models accounted for pen level 
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dependencies as random effects.  However, due to convergence issues, the animal level 
dependencies could not be accounted for within the linear regression model. 
 
3.4.       Results 
The blaCMY-2 and 16S rRNA gene copies per gram of wet feces were determined from 
community DNA extracted from all 2,424 fecal samples obtained from the trial.  There were 176 
steers studied in this trial for 26 days.  Fecal samples were collected every other day.  Forty 
samples from 7 animals could not be collected as the animal either became sick or died during 
the trial.  Further, blaCTX-M, tet(A), and tet(B) genes copies per gram of wet feces were 
determined from only 694 fecal samples obtained from Days 0, 4, 12, and 26 during the trial.  
These 4 days represent pre-treatment, effect of differential CCFA administration, effect of 
chlortetracycline administration, and the post-treatment washout phases, respectively.  All 
community DNA qPCR assays were run in triplicate. 
The multiple imputation technique was efficient in imputing reasonable values to the 
missing observations in the dataset.  This technique avoids a left-truncated distribution that is 
commonly observed since the assay cannot provide gene quantities values below the limit of 
quantification (LOQ); the LOQ of the assay being the lowest value observed among DNA 
samples as shown in Figures 3.1 and 3.2.  In our study, depending on the gene, there were as few 
as zero and as many as 435 missing observations.  The blaCMY-2 and 16S rRNA gene quantity 
datasets derived from all 2,424 community DNA samples (7,272 total observations) had 179 and 
0 missing observations, respectively.  The data obtained from a subset of community DNA 
samples from the selected four days had 44, 435, 2, and 431 missing observations for blaCMY-2, 
blaCTX-M, tet(A), tet(B) genes, respectively, from a the total of 2,084 observations.  In Figure 3.1 
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(i, ii), the histograms demonstrate the log10 blaCTX-M gene quantity distribution from raw and 
imputed data, graphed by the number of observations missing (n=0, 1, 2, or 3) among the 
triplicates of one community DNA extract (Figure 3.1 i, ii; sub graphs: A, B, C, and D).  Out of 
the 20 imputations performed, the histograms shown here are from the results of the single 
imputation to demonstrate the distribution of the gene copies before and after imputation 
procedure.  Sub graphs A, B, C, and D show the distributions of the observations that had no 
missing triplicates, one missing triplicate, two missing triplicates and all three missing triplicate, 
respectively.  The peak at -1.15 log10 gene copies in the non-imputed histograms represents the 
observations that were missing in each category.  The limit of quantification for the blaCTX-M 
gene real time PCR quantification assay was 1.82 log10 gene copies per gram.  The distribution is 
therefore left truncated at this quantification limit (Figure 3.1 i; subgraphs A, B, and C).  Figure 
3.1i; subgraph D shows the distribution of observations that had three missing triplicates.  It can 
be seen that the imputation process distributed these observations in a way that yielded many 
more observations below the 1.82 log10 gene copies quantification limit as compared to the 
single or double missing triplicates.  Similarly, raw and imputed gene distributions for the tet(B) 
gene are shown in Figure 3.2 i, ii.  The limit of quantification for the tet(B) gene was -0.56 log10 
gene copies.  Overall, the distribution of missing observations was shifted much more to the left 
(i.e., fewer gene copies) since the number of missing observations among triplicates increased.  
The marginal predicted means of blaCMY-2 log10 gene copy numbers per gram wet feces 
alone, and standardized to 16S rRNA gene copy numbers, stratified by the four treatment groups 
are shown in Figure 3.3A and B.  The baseline, Day 0, predicted mean log10 blaCMY-2 gene copies 
per gram wet feces (± SE) for the four treatment groups were 4.29±0.12, 4.52±0.12, 4.55±0.12, 
and 4.70±0.12.  The two treatment groups to which CCFA was administered to all steers within a 
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pen on Day 0 showed an increase on Day 4 in the log10 blaCMY-2 gene copies per gram as 
compared to the other two groups as shown in Figure 3.3 (sub graphs A and B).  
Chlortetracycline treatment starting after Day 4 led to further expansion of log10 blaCMY-2 gene 
copies per gram, both in the CCFA treated and non-treated group, as seen on Day 12. 
Figure 3.3C and Figure 3.4A and B shows the16S rRNA gene copies alone.  The 
baseline, Day 0, predicted mean log10 16S rRNA gene copies per gram ± SE for the four 
treatment groups were 10.06±0.05, 10.13±0.05, 10.10±0.05, and 10.01±0.05.  CCFA 
administration at different proportions did not lead to any significant changes in the total 16S 
rRNA gene copies per gram feces.  CTC seemed to increase the total 16S rRNA gene copies per 
gram feces.  The effect was more pronounced in the pens in which all steers had prior CCFA 
treatment.  The two way interactions of CTC and 6 sampling days (10 to 20) in the mixed linear 
model were highly significant (p<0.05). 
Effects of treatments on the absolute and standardized ceftiofur resistance (blaCMY-2 and 
blaCTX-M) gene copy numbers per gram wet feces for Days 0, 4, 12, and 26 are represented in 
Figure 3.4A and B, respectively.  Day 4 illustrates the effect only of CCFA on the ceftiofur 
resistance gene copies.  Fecal samples collected from animals in pens in which CCFA was 
administered to all the animals within the pen (Figure 3.4A and B, Day 4, depicted by dark navy 
and maroon lines) had a greater number of ceftiofur resistance determinants, blaCMY-2 and blaCTX-
M gene copies per gram, as compared to the other two treatment groups where CCFA was 
administered to one steer among 11 pen-mates.  In the latter pens ceftiofur resistance seemed to 
decrease mildly at the pen level on Day 4.  Day 12 in Figure 3.4A and B illustrate the effect of 
chlortetracycline on the absolute and standardized ceftiofur resistance gene copies, respectively.  
Chlortetracycline treatment was found to increase both blaCMY-2 and blaCTX-M gene copies per 
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gram as compared to the pens which did not receive chlortetracycline treatment (Figure 3.4A and 
B, Day12, depicted by dark navy and green lines).  The chlortetracycline effect was consistent 
across pens receiving CCFA at different proportions, suggesting that priming of animals/pens 
with CCFA was not required for chlortetracycline to have an effect.  
Effect of treatments on absolute and standardized tetracycline resistance [tet(A) and 
tet(B)] gene copy numbers per gram wet feces for the four days tested are represented in Figure 
3.5A and B, respectively.  CCFA significantly decreased both tet(A) and tet(B) genes copies per 
gram feces (Figure 3.5A and B, Day 4, depicted by dark navy and maroon lines) at the pen level 
as compared to the pens in which CCFA was administered to one steers among 11 pen-mates.  
As expected, there was also a marked increase in each of the tetracycline resistance tet(A) and 
tet(B) gene copies per gram feces following chlortetracycline treatment (Figure 3.5A and B, 
Day12, depicted by dark navy and green lines).  
 
3.5.       Discussion 
The hypothesis for this study was based on previous work that suggested that sparing 
chlortetracycline lowered the proportion of ceftiofur resistant E. coli isolates found in bovine 
feces [11].  In that study, chlortetracycline appeared to differentially favor E. coli population that 
were singly, doubly or triply resistant to tetracycline versus those in which ceftiofur and 
tetracycline resistance were both present and always with at least 6 other resistance types [11].  
The results of that study suggested the intriguing possibility for using chlortetracycline as an 
intervention to control ceftiofur, if only in the short term.  
In the present study, samples were evaluated by both culture-based [131-133] as well as 
metagenome-based assays.  This chapter focuses on the results obtained from the analysis of 
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resistance genes copies present in the entire fecal metagenome.  Also, the 16S rRNA gene copies 
were quantified to take into account the effect of treatment strategies on the total bacterial 
population.  
 In the present study, chlortetracycline did not reduce ceftiofur resistance in the fecal 
metagenome; in fact, gene copy numbers of both blaCMY-2 and blaCTX-M genes significantly 
increased following chlortetracycline treatment.  There are aspects of this study design that could 
have caused this discrepancy with the results of Platt et al.(2008) [11].  In the present study, 
either one or all animals within each of 8/16 pens received ceftiofur treatment prior to 
chlortetracycline treatment.  Initial ceftiofur exposure to animals might have changed the 
microbial gut population at the pen level enough to have modified the effect of CTC [132].  
Importantly, any chlortetracycline effect that would have been expected, unlike the previous 
study, would have been observed on a microbial population at disequilibrium.  
The blaCMY-2 gene has previously been quantified in two longitudinal trials; one in beef 
cattle [106] and one in dairy cattle [143], to evaluate the effect of ceftiofur treatment.  The 
former trial was an experimental study in which three different dose regimens of ceftiofur were 
compared.  The results of that study suggested that repeated regimens (three doses of 6.6mg/kg 
versus a single dose of 4.4 mg/kg) favored greater expansion of blaCMY-2 gene; however, there 
also was a concurrent reduction in the bacterial population among the total microbial fecal flora.  
Therefore, in these two regimens, higher group means of standardized log10 blaCMY-2 gene copies 
per gram were observed while lower group-means of non-standardized log10 blaCMY-2 gene copies 
per gram were observed following ceftiofur treatment.  The third regimen was more similar to 
the one used in the current study.  It consisted of a single dose of 6.6mg/kg.  Alali et al. (2009) 
showed [106] that the ceftiofur treatment significantly increased both the standardized as well as 
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non-standardized log10 blaCMY-2 gene copies per gram feces; in fact, this was similar to what was 
observed in our study.  The quantity of blaCMY-2 gene in our study also was comparable to earlier 
feedlot cattle study [106]; however, the blaCMY-2 gene quantities were lower for the dairy cattle 
study reported by Boyer et al.(2012) [143].  Those authors attributed this difference to the 
possibility that feedlot cattle likely harbor higher blaCMY-2 gene copies as compared to the dairy 
cattle because of the variation in management and environment.  All three studies have recorded 
a temporary increase in blaCMY-2 gene copies immediately following ceftiofur treatment.  We did 
not observe any significant effects on the 16S rRNA gene copies upon ceftiofur treatment.  In the 
earlier feedlot cattle study [106], the treatment group that received a similar ceftiofur dose to this 
study had overall higher predicted mean log1016S rRNA gene copies per gram when compared to 
the control group.  Results from both studies indicate that there was a selective advantage 
favoring expansion of ceftiofur resistance elements (and likely bacteria harboring same) as 
opposed to a significant reduction of overall bacterial community following ceftiofur treatment.  
The dairy cattle study [143] did not report quantification of a bacterial reference gene. 
The blaCTX-M gene was detected in E. coli [132-133] as reported earlier, and was also 
quantified from community DNA samples derived from feces in this study.  For both, the 
targeted ceftiofur resistance genes, blaCMY-2 and blaCTX-M gene copies per gram feces 
significantly increased in treatment groups where all animals were administered CCFA as 
compared to the pens where only one animal received CCFA treatment.  The short-term selection 
of blaCMY-2 gene copies following CCFA administration has been documented as mentioned 
before.  However, this is the first study to quantify blaCTX-M gene in feedlot cattle in the United 
States.  The quantities of tetracycline genes tet(A) and tet(B) significantly decreased in treatment 
pens where all animals were administered CCFA as compared to the pens where only one 
63 
 
animals received CCFA treatment.  Several phenotypic studies on E. coli in the past have 
recorded that all ceftiofur resistant isolates found in those study were co-resistant to tetracycline 
[11, 116, 124].  Therefore, the decrease in copies per gram wet feces of both of the tetracycline 
gene types from community DNA was not expected; however, it is readily explainable.  First, E. 
coli constitutes a small fraction of the entire microbial community.  That is, the microbial 
community constitutes of both culturable and non-culturable organisms that may or may not 
carry ceftiofur and tetracycline determinants together on one plasmid.  Secondly, even though 
those E. coli that remain following ceftiofur treatment are resistant to both ceftiofur and 
tetracycline, those bacteria that are resistant only to tetracycline do not survive, or else are 
suppressed.  The complexity of the co-selection or co-resistance mechanisms has been discussed 
by Doyle et al. (2013) [39].  Microbial population may evolve in a different ways under specific 
selection pressure in different niches depending on the complexity of the niches and the selection 
pressure, particularly if the starting bacterial population is not exactly the same.  Competitive 
bacterial interactions plays a critical role in niches like host gut harboring large numbers of 
varied microbes [39].  The blaCTX-M gene found among 29 out of these 88 study animals was 
reported to be harbored on IncN plasmid, among the E. coli isolates.  This plasmid was shown to 
be self-transmissible without conferring any additional resistance to the recipient E. coli [133].  
This indicated the presence of E. coli isolates that harbored plasmids which possessed resistance 
determinants towards ceftiofur alone. 
There were distinct differences observed between the E. coli (culture-based assay) results 
[131-132] and the gene quantification results obtained in this study.  The qPCR results from the 
community DNA indicated an increase in both blaCMY-2 and blaCTX-M gene copies per gram wet 
feces following chlortetracycline treatment.  This runs counter to the results obtained from E. 
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coli isolates where blaCMY-2 gene was differentially favored over the blaCTX-M gene [132].  
Similarly, tet(A) and tet(B) gene copies per gram wet feces significantly decreased in contrast to 
an increase in proportion of E. coli isolates harboring tet(A) and tet(B), following ceftiofur 
treatment [131].  These results clearly indicate the bias that can be introduced if conclusions 
regarding microbial populations are based solely on particular culturable organisms.  There is a 
huge unculturable microbial population that might well be expected to behave differently under 
similar selective pressures.  Further, it has been indicated before that the bacterial cells may also 
lose the entire plasmid or parts of the plasmid carrying resistance determinants, or the resistance 
genes may not be expressed under culturing stress [106].  Therefore, results from specific 
culturable organisms may incorrectly estimate the prevalence of target resistance gene among the 
gut flora.  The results from metagenome-based assays also have limitations; there may be 
multiple and varying amount of target gene copies per bacterial cell (relative abundance) among 
different bacterial species [106, 144].  The metagenome-based assay gives information about the 
overall target gene load in community DNA.  The information about variation of specific 
bacterial species carrying target genes is not provided from this assay.  Most antimicrobial 
resistance monitoring and surveillance systems across the world today test isolates and/or 
samples for antimicrobial resistance using culture-based methods.  Extrapolating the results 
obtained from specific culturable organisms (e.g. E. coli, Salmonella, or Campylobacter) to the 
entire microbial community may not be valid.  This can heavily influence the policies formulated 
by the regulatory bodies to control antimicrobial resistance in humans and animals.  Therefore, a 
metagenome-based component should be considered as part of a more holistic monitoring system 
to identify when contradictory or paradoxical results are seen in order to avoid such bias. 
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A multiple imputation procedure was used to deal with missing data in this study.  
Multiple imputation has been suggested to produce less-biased estimates and more accurate 
standard errors as compared to other approaches like single imputation, mean imputation, and 
complete case analysis [145].  However in a recent study, it was proposed that multiple 
imputation techniques did not improve a linear mixed model when missing data represented up 
to 40% of the sample set [146].  However, these authors acknowledged that multiple imputation 
procedure may be useful if such models included relevant predictor variables, which were not 
included in their linear mixed models.  We based our imputation model on unique animal 
identifier, sampling day, and the number of observations missing among the triplicate of each 
sample (i.e., 1, 2, or all 3 triplicates were missing).  The number of missing observations among 
the triplicates was considered as an important predictor similar to the previous study to impute 
missing quantitative real-time PCR data [143].  The histograms resulting from the imputed 
datasets, demonstrating log10 distributions of gene copies per wet gram feces, and based on the 
number of missing observations per triplicate, reveal that the distribution of missing observations 
shifts towards the left (including additional imputed observations at lower gene copies) as the 
number of missing values among triplicate increases.  For those observations where all three data 
points among the triplicates were missing were more likely to be assigned a lower value and also 
a value below the assay limit of quantification when contrasted to observations with either 
double or single missing values among the triplicates.  It was found to be a useful tool to handle 
missing data in order to obtain valid inference from parametric statistical models similar to the 
ones used in this study, whose assumptions depend on the integrity of underlying distributions.  
It is an effective procedure to analyze qRT-PCR data, which has moderate levels of missing 
values. 
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Overall, our study results indicate that chlortetracycline should not be used to control 
ceftiofur resistance.  Chlortetracycline treatment led to significant expansion of both blaCMY-2 
and blaCTX-M genes copies per gram wet feces in cattle pen previously exposed to ceftiofur in 
varying ratios of treatment.  Pen-level ceftiofur resistance elements were present in lower 
numbers in pens where one CCFA treated animal was co-housed with other non-treated pen-
mates.  Further studies with mixing at different treatment ratios should be conducted in order to 
establish the threshold of the co-mingling effect on levels of antimicrobial resistance.  In 
addition, there were distinct differences observed between culture-based results reported 
elsewhere [131-132] and the metagenome-based results obtained herein; this warrants further 
investigation as current worldwide antimicrobial resistance monitoring and surveillance systems 
tend to be based solely on culture-based approaches.  These may provide a biased picture of the 
changes occurring in the microbiome, depending largely on the organisms being observed.  The 
incorporation of gene quantification and other metagenome-based approaches in such 
surveillance systems may dramatically increase a more holistic understanding in this sphere of 
antimicrobial resistance.
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176 steers; 16 pens; 4 treatment groups 
 
Group 1 Group 2 Group 3 Group 4 
  
4 pens, 11 steers each 
 
 
- All 11 steers receive    
CCFA; 6.6 mg/kg 
once Day 0 
 
- CTC 22mg/kg; 3   
  treatment regimens- 5   
day each 
 
 
4 pens, 11 steers each 
 
 
-All 11 steers receive  
CCFA; 6.6 mg/kg 
once Day 0 
 
-No CTC Treatment 
 
 
4 pens, 11 steers each 
 
 
-One among 11 steers 
receive CCFA; 6.6 
mg/kg once Day 0 
 
-CTC 22mg/kg; 3 
treatment regimens- 5 
day each  
 
 
4 pens, 11 steers each 
 
 
-One among 11 steers 
receive CCFA; 6.6 
mg/kg once Day 0 
 
-No CTC treatment  
 
 
Table 3-1 Schematic representation of the study design. 
The two interventions were assigned in a two-way full factorial manner.  Number of pens 
assigned to each treatment and number of animals within each of the pens are shown above. 
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Table 3-2 Primers used for PCR reactions 
a Primer set used are from Alali et al. [106] 
b Primer set used are from Steinman et al. [147] 
c Primer set used are from Ng et al. [148] 
d Primer set used are from Cottell et al. [133] 
1 Broad range primers to generate template for the standard curve 
2 Narrow range primers for sample quantification 
* Sequence used for primer design
Gene name Primer Primer  Sequence Expected Product 
Size (bp) 
GenBank Accession no.*  
blaCMY-2 585F 5'- CAG ACG CGT CCT GCA ACC ATT AAA -3' 
454 a,1 
AB212086 
1038R 5'- TAC GTA GCT GCC AAA TCC ACC AGT -3' 
675F 5'- AGG GAA GCC CGT ACA CGT T -3' 
64 a,2 
738R 5'- GCT GGA TTT CAC GCC ATA GG -3' 
16S rRNA 1056F 5' - AAT GTT GGG TTA AGT CCC GCA ACG - 3' 
400 a,1 
EU014689 
1456R 5' - ATG ATC ACA AAG TGG TAA GCG CCC - 3' 
P201 5'- GAG GAA GGI GIG GAI GAC GT - 3' 
216 b,2 
P1370 5' - AGI CCC GIG AAC GTA TTC AC - 3' 
tet(A) tet(A)(F) 5' -GCTACATCCTGCTTGCCTTC- 3' 
210 c X61367 
tet(A)(R) 5' -CATAGATCGCCGTGAAGAGG- 3' 
tet(B) tet(B)(F) 5' -TTGGTTAGGGGCAAGTTTTG- 3' 
659 c J01830 
tet(B)(R) 5' -GTAATGGGCCAATAACACCG- 3' 
blaCTX-M CTX-M(F) 5' -ATGTGCAGYACCAGTAA- 3' 
536d AY143430_CTX-M-24 
CTX-M(R) 5' -CCGCTGCCGGTYTTATC- 3' 
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Figure 3.1 Histograms illustrating (i) overall raw distribution of log10 blaCTX-M gene copies 
per gram feces and, (ii) distribution of log10 blaCTX-M gene copies per gram feces with a 
single imputation, subgraphed by the number of missing observations (A=0, B=1, C=2, 
D=3) among the PCR triplicate assays.  Note: * represents missing observations. 
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Figure 3.2 Histograms illustrating: (i) overall raw distribution of log10 tet(B) gene copies 
per gram feces and, (ii) distribution of log10 tet(B) gene copies per gram feces with a single 
imputation, subgraphed by the number of missing observations (A=0, B=1, C=2, D=3) 
among the PCR triplicate assays.  Note: * represents missing observations. 
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Figure 3.3 Line graphs illustrating (A) non-standardized log10 blaCMY-2 (B) standardized (as 
ratio to log10 16S rRNA) log10 blaCMY-2, and (C) log10 16S rRNA gene copies per gram wet 
feces, by treatment groups and over days.   
Dark navy line (with solid square) is for the pens in which CCFA was administered to all 
the steers within pens followed by CTC administration at the pen level; green (with hollow 
square) is for the pens in which CCFA was administered to a single steer within the pens 
followed by CTC administration at the pen level; maroon line (with solid triangle) 
represents pens in which CCFA was administered to all steers within pens without 
subsequent CTC administration at the pen level; and orange lines (with hollow triangle) 
represents pens in which CCFA was administered to a single steer within the pens without 
subsequent CTC administration at the pen level. 
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Figure 3.4 Line graphs illustrating (A) non-standardized log10 blaCTX-M (dashed lines), non-
standardized log10 blaCMY-2(solid lines),  and log10 16S rRNA (dashed and dotted lines) gene 
copies per gram wet feces (B) standardized (as ratio to log10 16S rRNA) log10 blaCTX-M 
(dashed lines) and log10 blaCMY-2 (solid lines) gene copies per gram wet feces, by treatment 
groups and over days. See Figure 3.3 for treatment groups key. 
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Figure 3.5 Line graphs illustrating (A) non-standardized log10 tet(B) (dashed lines), non-
standardized log10 tet(A) (solid lines),  and log10 16S rRNA (dashed and dotted lines) gene 
copies per gram wet feces (B) standardized (as ratio to log10 16S rRNA) log10 tet(B) (dashed 
lines) and log10 tet(A) (solid lines) gene copies per gram wet feces, by treatment groups and 
over days. See Figure 3.3 for treatment groups key.
0
2
4
6
8
10
   
   
   
  t
et
(B
)  
   
   
   
 te
t(A
)  
   
   
   
   
   
   
   
   
 1
6S
rR
N
A
0 4 12 26
Days
-1
0
-9
.5
-9
-8
.5
-8
-7
.5
-7
-6
.5
-6
-5
.5
-5
-4
.5
-4
te
t(B
)  
   
   
   
   
   
   
   
   
 te
t(A
)
0 4 12 26
Days
Lo
g 1
0 g
en
e 
co
pi
es
 
St
an
da
rd
iz
ed
 L
og
10
 g
en
e 
co
pi
es
 
75 
 
 
Chapter 4 
Effects of ceftiofur and chlortetracycline on antimicrobial susceptibility and 
on tet(A), tet(B), and blaCMY-2 genes among E. coli isolated from cattle feces  
 
4.1.       Abstract 
A randomized controlled field trial was conducted to evaluate the effects of two treatment 
strategies on ceftiofur and tetracycline resistance in feedlot cattle.  The strategies consisted of 
ceftiofur crystalline-free acid (CCFA) administered either to one or else to all of the steers within 
a pen; followed by feeding, or else not feeding, a therapeutic dose of chlortetracycline (CTC).  
Eighty-eight steers were randomly allocated to 8 pens of 11 steers each.  Both treatment 
regimens were randomly assigned to the pens in a two-way full factorial design.  Non-type-
specific (NTS) E. coli (n=1,050) were isolated from fecal samples gathered on Days 0, 4, 12, and 
26.  Antimicrobial susceptibility profiles were determined using a microbroth dilution technique.  
PCR was used to detect tet(A), tet(B), and blaCMY-2 genes within each isolate.  Chlortetracycline 
administration greatly exacerbated the already increased levels of both phenotypic and genotypic 
ceftiofur resistance favored by prior CCFA treatment (P<0.05).  The 4 treatment regimens also 
influenced the phenotypic multidrug resistance count of NTS E. coli populations.  
Chlortetracycline treatment by itself was associated with an increased probability of selecting 
isolates that harbored tet(B) versus tet(A) (P<0.05); meanwhile, there was an inverse association 
between finding tet(A) versus tet(B) genes for any given regimen (P<0.05).  The presence of a 
tet(A) gene was associated with an isolate exhibiting reduced phenotypic susceptibility to a 
higher median number of antimicrobials (n=289, median=6; 95% CI= 4-8) as compared to the 
tet(B) gene (n=208, median=3; 95% CI= 3-4).  Results indicate that chlortetracycline can 
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exacerbate ceftiofur resistance following CCFA therapy and therefore should be avoided, 
especially when considering their use in sequence.  Further studies are required to establish the 
animal-level effects of co-housing antimicrobial-treated and non-treated animals together. 
 
4.2.       Introduction 
Antimicrobial resistance is of global public health concern as it can exert enormous 
clinical and financial burdens on health care systems worldwide [149-150].  Antimicrobials are 
widely used in animal agriculture as therapeutic, prevention, control, and growth promotion 
agents [151].  Though not without controversy, several reports have indicated that antimicrobial 
use in food animals has been associated with subsequent development of resistance to 
antimicrobials in bacterial pathogens from humans [74-76].  Various intervention strategies have 
been proposed or else established by regulatory organizations around the world in an attempt to 
address this problem.  Such strategies include: 1) banning of antibiotics as agricultural growth 
promoters [152-153], 2) removing certain antibiotic classes from the market and, 3) 
recommending that some classes of antibiotics never be approved for food animal use [154].  
While an outright ban or removal of antimicrobials might eventually result in reduced resistance, 
such actions may also impede the veterinarian’s or producer’s ability to prevent, control, and 
treat diseases; paradoxically, this could actually increase public health risk [155-156].  There is 
an urgent need to better understand those factors that contribute to the dissemination, 
propagation, and persistence of antimicrobial resistance determinants among both commensal 
and pathogenic enteric bacteria and to design treatment strategies at the animal, pen, and farm 
levels to control and mitigate this global problem [157]. 
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Ceftiofur, a 3rd generation cephalosporin, belongs to the same general class of antibiotics 
as ceftriaxone and is classified as a critically important antibiotic by the World Health 
Organization [5].  Ceftriaxone is highly valued in human medicine, especially for treating 
invasive salmonellosis in children [122-123].  Resistance to ceftiofur is regarded as problematic 
since shared resistance determinants may confer resistance to ceftriaxone. This paper describes a 
study designed to evaluate the effects of two different treatment strategies on phenotypic and 
genotypic ceftiofur resistance among non-type-specific Escherichia coli isolates in feedlot cattle. 
The first treatment strategy was to evaluate the differential effect of whole-pen versus individual-
animal level ceftiofur treatment (ceftiofur crystalline-free acid: CCFA, a long acting ceftiofur 
formulation).  The whole-pen treatments with CCFA were meant to mimic a ‘metaphylaxis’ or 
‘control’ label use such as for a bovine respiratory disease (BRD) outbreak in feeder cattle. On 
the other hand, single individual-animal treatment in a pen of otherwise untreated and healthy 
cattle were meant to mimic the sporadic treatment of BRD cases.  Among pens in which only a 
single animal received the CCFA therapy, the remaining animals were expected to serve as a 
ready source of more susceptible enteric bacteria, useful for repopulating the gut flora of treated 
cattle.  Though far from unanimous agreement, many scientists accept that antibiotic-resistant 
bacteria carry resistance genes at a relative fitness cost [10, 136].  Readily available susceptible 
bacteria – bacteria devoid of the resistance gene – may help to promote rapid re-colonization of 
the host gut (treated animal) by outcompeting resistant bacteria that tend to dominate post-
treatment periods [137].  This study exploited these principles to determine if re-colonization 
was affected by higher levels of exposure to susceptible bacteria, or even to those bacteria 
resistant to other antimicrobials.   
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The second treatment strategy was to feed chlortetracycline (CTC) at therapeutic doses 
following CCFA treatment.  Our previous work had demonstrated  that chlortetracycline   
resulted in a temporary decrease in the prevalence of ceftiofur resistant E. coli, especially while 
it was being administered in the feed [11].  Chlortetracycline treatment in the study by Platt et al. 
(2008) appeared to differentially favor E. coli isolates that were singly resistant to tetracycline 
versus those that exhibited both ceftiofur and tetracycline resistance.  Those earlier results 
suggested that chlortetracycline might help to minimize the proliferation and accumulation of 
ceftiofur resistant bacteria in animal agriculture settings.  Our second treatment strategy was 
designed based on those results.  We hypothesized that chlortetracycline would expedite the 
return to baseline levels of ceftiofur resistance among non-type-specific NTS E. coli, whether 
following metaphylaxis or individual therapy indications.  Our focus was on pen-level 
interpretations: both for treatments and for outcomes.  This is consistent with aiming to reduce 
the overall carriage of resistant bacteria in truckloads of cattle shipped to slaughter. 
The effects of these 2 treatment strategies (i.e., differential CCFA treatment and 
subsequent chlortetracycline administration) were determined by examining the susceptibility 
profiles and the differential selection and co-selection of ceftiofur and tetracycline resistance 
genes among NTS E. coli isolates from cattle feces.  Further, associations of the resistance genes 
among themselves and with the various phenotypic multidrug resistant (MDR) counts obtained 
were evaluated.  The phenotypic MDR counts in this study are defined as the number of 
antimicrobials (present on a single 15-drug panel) towards which an isolate exhibits phenotypic 
resistance.  These observations were explored further in this study to better explain the 
phenomena observed in the current as well as in the earlier trial by Platt et al. [11].  This aided in 
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understanding the factors behind the development and accumulation of multidrug resistance 
determinants.   
 
4.3.       Methods 
Study Design A 26-day randomized controlled trial was conducted at a research feedlot 
located at West Texas A&M University in Canyon, TX.  All procedures used were reviewed and 
approved by the Amarillo-Area Cooperative Research, Education, and Extension Triangle 
Animal Care and Use Committee (Protocol No. 2008-07), and by the Clinical Research Review 
Committee at Texas A&M University (CRRC # 09-35). 
Eighty-eight steers were allocated to 8 pens of 11 steers each, such that the average pen 
steer weights were similar.  The 2 pen-level treatment strategies were randomly assigned to these 
8 pens in a complete two-way full factorial design resulting in four different treatment groups.  
Factor 1 was whether all 11 animals in a pen versus one out of 11 animals were treated with 
CCFA.  Factor 2 was a follow-up chlortetracycline regimen; referring to cattle in pens receiving 
chlortetracycline in feed following the CCFA regimens.  A third factor (not randomized) in the 
statistical models was the effect of day of study (period) on the level of antimicrobial resistance 
measured in each of the phenotypic and genotypic endpoints.  The drugs, dosages, routes of 
administration, and treatment regimens are presented in Table 4-1. 
All steers in 4 out of 8 pens were given CCFA treatment (Excede®, Pharmacia & Upjohn 
Co, Division of Pfizer Inc, New York, NY) as a single dose regimen of 6.6 mg/kg administered 
subcutaneously at the base of the ear) on Day 0.  This is a recommended labeled dose and route 
of administration for treatment of bovine respiratory disease (BRD) and bovine foot rot and for 
the control of BRD.  Two of these pens each received 3 separate 5-day regimens (with a one-day 
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break in between) of 22mg/kg chlortetracycline (Aureomycin®, chlortracycline complex 
equivalent to 220.5 g of chlortetracycline/ kg, Alpharma, Bridgewater, NJ) via topdressing after 
the morning feed was delivered, according to the label directions and starting at Day 4.  A 
therapeutic labeled dose of chlortetracycline, recommended for the control and treatment of 
bacterial conditions like pneumonia caused by Pasteurella multocida, was used.  The three 
consecutive 5-day treatment regimens were administered in a similar manner to our previous 
study [11] to better aid in inter-study comparisons.  In the remaining 4 pens, CCFA was 
administered only to 1 out of 11 steers within the pen.  In just 2 of these pens, chlortetracycline 
was likewise given to all animals on the same schedule and dosing regimen as described above 
(Figure 4.1).  
 
Sample collection 
At 06:00 every other day, steers were restrained in a squeeze chute.  Fecal grab samples 
of approximately 50 g were collected per rectum with a new obstetric sleeve glove and placed in 
individual plastic cups.  All samples were transported on ice to the laboratory on the day of 
sample collection.  Fecal samples were mixed with glycerol at a 1:1 ratio; 4 ml of the mixture 
was added to 5 ml cryo-vials and stored at -70°C for further bacterial culture and isolation as 
well as phenotypic and genotypic analysis of same.  Two fecal samples were not collected due to 
the death of a single steer late in the study period.  
 
Isolation of non-type-specific E. coli 
A microbiological culture-based method was used for NTS E. coli isolation from the 
glycerol-preserved frozen samples.  The procedures for the NTS E. coli isolation and 
antimicrobial susceptibility testing were adapted from previous work [11].  Briefly, 200 
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milligrams of fecal sample was mixed with 1.8 milliliter of buffered peptone water and the 
suspension was streaked onto MacConkey agar (BD Difco™, Sparks, MD) for NTS E. coli 
isolation.  Plates were incubated at 37° for 18-24 hours.  Further, 3 separate and distinct colonies 
(slightly convex, magenta-colored colonies surrounded by a dark pink area) were streaked on 3 
separate MacConkey plates and were incubated for 18-24 hours.  This step was added to the 
protocol in order to assure we obtained pure cultures of NTS E. coli.   
We performed a quality control experiment to test if this single extra passage would lead 
to the loss of plasmid/resistant determinants and thereby cause significant differences in the 
susceptibility results.  The head-to-head experiment was conducted on 33 E. coli isolates derived 
from Day 4 fecal samples.  These samples were obtained from 3 pens in which all animals 
received CCFA treatment.  The results revealed an extremely high level of agreement (median қ 
=0.93) between the susceptibility results obtained from either a single, or double passage for all 
15 antimicrobials.  The paired t-test, comparing the MIC values and testing resistant proportions 
between the two groups, also revealed no significant differences between the results obtained 
from the two passage approaches (p>0.05).  Therefore, we concluded that an extra passage did 
not lead to significant differences in antimicrobial susceptibility results, but aided in assuring we 
had pure cultures to perform further phenotypic and genotypic analyses.  An indole spot test was 
performed on each isolate. While not definitive for E. coli, when combined with the prior 
probabilities that arise from the selective medium and the morphological selection (including 
lactose fermentation) the post-test probabilities are well in excess of 99% [116], Previous work 
[116] has suggested that there is little advantage of biochemical confirmation of NTS E. coli 
isolates over simple morphological selection of a typical colony obtained from MacConkey agar; 
in that study, biochemical assays confirmed 99.9% of the typical colonies on MacConkey agar to 
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be E. coli.  A single colony from each of the 3 MacConkey plates was streaked to 3 separate 
Tryptic soy agar plates (BD Difco™, Sparks, MD) and was incubated for 18-24 hours.  The NTS 
E. coli isolates from the TSA plates were further used for the antibiotic susceptibility testing.  
DNA from NTS E. coli isolates was extracted for genotypic analysis by suspending a 
colony in 500µl of nuclease free water (Qiagen, Valencia, CA) and then heating the suspension 
at 95°C for 10 minutes.  The NTS E. coli DNA samples were stored at -20°C for further 
qualitative detection of tet(A), tet(B), and blaCMY-2 genes.  The plasmids encoding (blaCMY-2) 
gene is predominantly associated with ceftiofur resistance from both humans and animals 
isolates in the United States [31-32, 158].  Therefore, the blaCMY-2 gene was chosen to predict the 
genotypic ceftiofur resistance among the isolates.  The two tetracycline genes [tet(A) and tet(B)] 
were chosen as they have been reported to be the most abundant tetracycline resistance genes 
detected among E. coli in cattle in the United States [61].   
 
Antimicrobial susceptibility testing of non-type-specific E. coli isolates  
Fecal samples from all animals in all 8 pens representing all 4 treatment combinations on 
Days 0, 4, 12, and 26 were analyzed.  Three NTS E. coli isolates from a total number of 350 
fecal samples each (1,050 NTS E. coli isolates) were tested for their antimicrobial susceptibility 
profile and gene presence.   
Two to three distinct NTS E. coli colonies were picked from the TSA plates, mixed and 
then suspended into 4 ml of sterile deionized water to adjust to a 0.5 McFarland standard.  Ten 
microliters of the suspension was mixed with Mueller-Hinton broth and 50µl of the suspension 
was inoculated to each well of a Sensititre plate using the SensititreTM automated inoculator 
(Trek Diagnostic Systems, Cleveland, OH).  The plates were incubated at 37°C for 18hours.  
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Minimum inhibitory concentrations (MIC) were determined for 15 different antibiotics via the 
broth micro-dilution method using the gram negative NARMS panel CMV1AGNF (Trek 
Diagnostic Systems, Cleveland, OH) [159].  The plates were read by the Sensititre ARIS® 
automated system (Trek Diagnostic Systems, Cleveland, OH).  The Sensititre ARIS® automated 
system interprets isolates as susceptible, intermediate, or resistant according to Clinical and 
Laboratory Standards Institute (CLSI) guidelines [160].  For our purposes, those isolates 
demonstrating intermediate susceptibility towards antimicrobials were re-classified as 
susceptible so as to utilize a binary classification in the data analysis.  For those antibiotics 
without breakpoints established by the CLSI guidelines, we instead used ‘consensus’ breakpoints 
established by the National Antimicrobial Resistance Monitoring System (NARMS) for enteric 
bacteria [161]  (see Table 4-3).  Escherichia coli ATCC 25922, Escherichia coli ATCC 35218, 
Pseudomonas aeroginosa ATCC 27853, Staphylococcus aureus ATCC 29213, and Enterococcus 
faecalis ATCC 29212 (American Type Culture Collection, Manassas, VA) were used as quality 
control strains for susceptibility testing.  The MIC results obtained from these quality control 
strains were compared to the quality control ranges recommended by the Clinical and Laboratory 
Standards Institute [162].  The quality control was performed for every new batch of Mueller-
Hinton broth used and also for every new batch of microbroth dilution susceptibility plates.  
 
Genotypic qualitative detection of resistance genes 
A duplex PCR assay to detect both tet(A) and tet(B) was performed as previously 
described [163] using DNA extracted from the same 1,050 NTS E. coli isolates for which 
antibiotic susceptibility test was conducted.  The blaCMY-2 PCR was performed as previously 
described [106].  The primers used for all PCR reactions are listed in Table 4-2.  Promega® PCR 
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mastermix (Promega Corp., Madison, WI) was used for both assays.  All reactions were carried 
out in Eppendorf Mastercycler® gradient thermal cyclers (USA Scientific, Inc., Ocala, FL).  
Automated capillary electrophoresis analysis of the PCR product for all 3 resistance genes was 
performed via the QIAxcel System (QIAgen, Valencia, CA). 
Controls: The positive control used for the duplex reaction was a 1:1 mixture of the DNA 
obtained from E. coli ATCC 47042 and the XL1-Blue E. coli strain.  E. coli ATCC 47042 is 
known to harbor the tet(B) gene and XL1-Blue E. coli strain harbors the tet(A) gene.  E. coli 
strain (M1) was used as the positive control for the blaCMY-2 gene.  It was previously obtained 
from the University of Illinois, Chicago [139].  This strain is known to harbor the blaCMY-2 gene.  
The negative control consisted of the master mix alone. 
 
Statistical Methods:  
Descriptive Statistics: The outcome measures (and data types) were: 1) proportion of 
resistant (versus susceptible) NTS E. coli isolates for each of 15 antimicrobials (binary), 2) log2 
MIC for each of 15 antimicrobials (truncated integer), and 3) presence (or absence) of 3 different 
resistance genes (binary).  Basic descriptive statistics were computed by cross-tabulating each of 
these outcomes across 4 sampling days for each treatment group.  The phenotypic MDR count of 
an isolate was determined by establishing the total number of antimicrobials to which an isolate 
was phenotypically resistant, out of the 15 antimicrobials tested on the NARMS panel.  The 
overall frequency distribution of the phenotypic MDR counts among isolates in all 4 groups was 
examined.  These distributions were compared to evaluate the treatment effect.  Similarly, the 
three resistance genes’ presence (or, absence) was cross-tabulated by treatment and day, as well 
as with the phenotypic MDR counts obtained from the NARMS panel.  Significance of 
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associations was determined by likelihood ratio chi-square test.  Distributions of MIC for each of 
the 15 antimicrobials, cross-tabulated by treatment and day, were also examined. 
 
Multivariable analysis to evaluate the treatment effects on phenotypic and genotypic resistance 
among non-type-specific E. coli: 
Generalized estimating equations (GEE) with binomial error distribution and logit link 
functions were used to analyze the data (STATA® SE Release 12.1; STATA Corp., College 
Station, TX).  This approach was used to simultaneously evaluate the risk factors for isolates 
exhibiting phenotypic expression of ceftiofur resistance and also for isolates harboring blaCMY-2, 
tet(A), and tet(B) genes separately.  All GEE models were adjusted for the pen-level 
dependencies assuming exchangeable correlation structures at the pen level.  There also were 
dependencies expected among the three isolates derived from a single fecal sample on each day; 
however, pen- and animal-level dependencies both could not simultaneously be accounted for 
due to convergence problems in the multi-level mixed logistic model.   
The factors that resulted in isolates with higher phenotypic MDR counts (number of 
antimicrobials towards which an isolate exhibited resistance) were analyzed using ordinal 
logistic models.  There were a maximum of 12 out of 15 antimicrobials against which resistances 
were exhibited by isolates in this study.  Therefore, there were 13 different categories (e.g. pan-
susceptible, single-, double-, penta-, deca-, dodeca-resistant) depending on the number of 
antimicrobials to which an isolate exhibited resistance.   
Logistic regression models for discrete-time survival analysis were used to model 
treatment factor effects on the ability of NTS E. coli isolates to grow/survive over each of the 
increasing ceftiofur concentrations, as tested on the NARMS panel [164].  This approach 
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allowed for right-censoring of the MIC data at the highest recorded concentration present on the 
panel. 
 
4.4.       Results 
Descriptive statistics 
The distributions of minimum inhibitory concentrations for all 15 antibiotics among the 
1,050 NTS E. coli isolates tested are shown in Table 4-3.  Out of 1,050 NTS E. coli isolates, 
resistance to at least 1 antimicrobial was detected in 710 (67.62%) isolates; 340 (32.38%) 
isolates were found to be susceptible to all 15 antimicrobials tested.  The most common 
resistance was detected against tetracycline (642 [61.14%] isolates), ampicillin (391 [37.24%] 
isolates), sulfisoxazole (329 [31.33%] isolates), streptomycin (308 [29.33%] isolates), 
ceftriaxone (267 [25.43%] isolates), chloramphenicol (246 [23.43%] isolates), and ceftiofur (241 
[22.95%] isolates) as shown in Table 4-3.  
The frequency distribution of the E. coli isolates by the phenotypic MDR count for all 4 
treatment groups is shown in Figure 4.2.  The pens in which CCFA was administered to 1 out of 
11 steers within the pens and chlortetracycline treatment was not administered experienced the 
least antimicrobial selection pressure (Figure 4.2B).  Within this treatment group, 55.1% of the 
isolates were pan-susceptible to the panel of 15 antimicrobials; in addition, the distribution was 
highly right-skewed indicating decreasing numbers of greater phenotypic MDR counts in this 
group (Figure 4.2B).  A higher prevalence of greater phenotypic MDR counts was identified in 
isolates from animals within pens where CCFA was administered to all the animals within the 
pens, but likewise were not subsequently fed chlortetracycline in feed (Figure 4.2A and B).  The 
frequency distribution of phenotypic MDR counts in this treatment group (illustrating CCFA 
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treatment alone) was more uniformly distributed over the full range of multidrug resistant 
numbers (0-15); in this case,  41% of the isolates were found to be pan-susceptible to all 15 
antimicrobials (Figure 4.2A).  The effect of chlortetracycline alone was best illustrated by the 
contrasts among the pens in which only 1 among 11 animals had prior CCFA exposure (Figure 
4.2B and D).  Chlortetracycline exposure increased the prevalence of higher phenotypic MDR 
counts (Figure 4.2D); however, chlortetracycline tended to select for lower MDR categories 
(isolates resistant to one or two antimicrobials) rather than categories with ≥ 5 antimicrobials.  
The chlortetracycline effect was much more profound when it followed CCFA treatment applied 
to all animals in a pen (Figure 4.2C).  These pens illustrated the maximum CCFA and 
chlortetracycline treatment effects (Figure 4.2C) and isolate profiles illustrated a highly uniform 
distribution with a quite remarkable 3.03% of NTS E. coli isolates resistant to 12 antimicrobials. 
Overall, tet(A), tet(B), and blaCMY-2 genes were harbored by 289, 208, and 139 isolates, 
respectively, among the 1,050 NTS E. coli isolates (Figure 4.3); 564 isolates were negative for 
all 3 resistance genes.  There were only 3 isolates that harbored blaCMY-2 alone; that is, without 
tet(A) or tet(B).  The majority of blaCMY-2 positive isolates also harbored the tet(A) gene (n=120), 
while the blaCMY-2 gene was much less prevalent among the isolates also harboring the tet(B) 
gene (n=23).  There were only 14 isolates that harbored tet(A)and tet(B) genes together; further, 
there were 7 isolates that were positive for all 3 resistance genes (Figure 4.3). 
The association of a particular gene, or gene combination, with the phenotypic MDR 
count was evaluated and illustrated by way of the Box-plot (Figure 4.4).  Overall, the presence of 
the tet(A) gene (n=289) was associated with isolate phenotypes exhibiting reduced susceptibility 
to a higher median number of antimicrobials (median=6,  95% CI= 4-8) as compared to the 
tet(B) gene (n=208; median=3,  95% CI= 3-4).  Similarly, blaCMY-2 gene-positive isolates were 
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associated with very high phenotypic MDR count (n=139; median= 9).  The 564 isolates that 
were found to be negative for all three resistance genes were generally pan-susceptible (median 
number of antimicrobials = 0) (Figure 4.4).  The 162 isolates harboring only tet(A), in the 
absence of tet(B) and blaCMY-2, exhibited phenotypic resistance towards a median number of 2 
antimicrobials.  Isolates, when positive to both tet(A) and blaCMY-2 and in the absence of tet(B) 
(n=113), exhibited a higher phenotypic MDR count (median = 9 antimicrobials); on the other 
hand, isolates positive for only tet(B), but in the absence of tet(A) and blaCMY-2 (n=178), were 
resistant to a median of 3 antimicrobials.  In Figure 4.4, the Box-plot graphic clearly 
demonstrates that the presence of blaCMY-2 gene was associated with higher phenotypic MDR 
counts. 
 
Multivariable analysis to evaluate the treatment effects on phenotypic and genotypic resistance 
among non-type-specific E. coli: 
Generalized estimating equation (GEE) with three-way full factorial designs were used to 
evaluate the effects of the treatment strategies on resistance, measured both at genotypic and 
phenotypic levels.  The three factors corresponded to: CCFA administered to either one or all the 
animals within pens (Mix; binary variable), chlortetracycline administration to all animals within 
a pen (CTC; binary variable), and study period (Day 0, 4, 12, or 26; categories coded as an 
indicator variable with 0 as referent) respectively.  Importantly, results are interpreted at the pen-
level, not at the individual-animal level. 
 Figure 4.5 illustrates the prevalence of NTS E. coli isolates exhibiting both phenotypic 
resistance to ceftiofur (shown by the solid line) and the presence of blaCMY-2 (shown by the 
dashed line).  The likelihood of recovering ceftiofur-resistant NTS E. coli or blaCMY-2 positive 
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isolates tended to increase following CCFA administration (Figure 4.5 A, C; Day 4).  
Chlortetracycline treatment delayed the return of ceftiofur resistance to the baseline (Figure 4.5 
C, D; Day12).  In fact, chlortetracycline appeared to have favored the expansion of the ceftiofur 
resistant population, fully independent of the prior CCFA regimen.  Importantly, phenotypic 
ceftiofur resistance was not completely associated with the presence of blaCMY-2 gene at all time 
points, nor in all 4 treatment groups.  There were multiple isolates (n=102) that exhibited 
phenotypic ceftiofur resistance but did not harbor the blaCMY-2 gene.  This can best be 
appreciated by the gap between the line graphs illustrating phenotypic versus genotypic (blaCMY-
2) ceftiofur resistance in Figure 4.5.  Further characterization of the non-blaCMY-2 isolates has 
been carried out to explain this difference and results were reported elsewhere [133]. 
The likelihood of recovering isolates expressing tetracycline resistance, as well as isolates 
harboring tetracycline resistance genes, increased with CCFA administration (Figure 4.6 A, C; 
Day 4).  As was expected, chlortetracycline treatment further increased tetracycline resistance, 
both at phenotypic and genotypic levels (Figure 4.6 C, D; Day 12).  Importantly, there was a 
differential selection favoring isolates harboring tet(A) over tet(B) following CCFA treatment 
administered to all steers within a pen (Figure 4.6C; Day 4).  However, when only 1 steer in a 
pen of 11 animals received prior CCFA treatment, there was a clear preferential selection 
favoring isolates harboring tet(B) gene over tet(A) once chlortetracycline was administered in the 
feed (Figure 4.6 D; Day 12).  
 
The association between treatment strategies and the phenotypic MDR count was 
assessed using an ordinal logistic model with a three-way full factorial design (Mix, CTC, and 
Day) as outlined above.  Phenotypic MDR count was defined in this study as the number of 
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antimicrobials towards which an isolate exhibited (binary) resistance, out of the panel of 15 
antimicrobials tested on the NARMS panel.  The treatment groups in which all steers received 
CCFA were observed to have a significant decrease in the proportion of isolates that were pan-
susceptible (Figure 4.7 A, Day 4).  There also was a significant effect of CCFA treatment on 
increasing the likelihood of recovering penta- or deca-resistant isolates (Figure 4.7 B & C, Day 
4).  This was in marked contrast to the groups in which only 1 animal among 11 in a pen 
received CCFA treatment.  Less markedly, though also significant, feeding of chlortetracycline 
lowered the probability of isolates being pan-susceptible when compared to pens of cattle that 
did not receive chlortetracycline (Figure 4.7 A, Day 12).  Chlortetracycline administration was 
also associated with increased odds for recovering both penta- and deca-resistant isolates, 
especially notable when prior CCFA treatment was administered to only one among 11 steers 
within the pen (Figure 4.7 B & C, Day 12).  When CCFA was administered to all steers, 
subsequent chlortetracycline administration appeared to sustain the penta-resistant proportion 
while further increasing the deca-resistant NTS E. coli proportion of isolates.  Overall, CCFA 
appeared to have the more dramatic effect on selection of higher phenotypic MDR counts (penta- 
or deca- resistant) than chlortetracycline alone; however, chlortetracycline greatly exacerbated 
the prior effects of CCFA on phenotypic MDR counts. 
 
A discrete-time logistic model was used to compare among the 4 treatment groups the 
proportion of NTS E. coli isolates that were able to grow (i.e., were not inhibited) over each of 
the increasing ceftiofur concentrations on the NARMS panel.  The fixed effects for the model 
consisted of Mix, CTC, and ‘survival time’ (survival time here was an analog for each increasing 
concentration of ceftiofur tested on NARMS panel).  The two-way interactions with ‘time’ were 
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statistically insignificant in the model and therefore were excluded from the final model.  
Survival curves represent the predicted probabilities of NTS E. coli isolates not being inhibited at 
each increasing concentration of ceftiofur; ceftiofur concentration is graphed as zero-adjusted 
and ordered log2 transformed (MIC) values for all 4 groups (Figure 4.8).  The two reference lines 
in Figure 4.8 indicate that the two treatment groups in which all steers received CCFA treatment 
had 26% and 17% of isolates that were not inhibited even at the highest concentrations of the 
ceftiofur tested on the NARMS plate (log2 (8 µg/ml) + 4 = 7).  These proportions were 
considered right-censored and were significantly higher than in the groups in which only one 
animal among 11 in a pen that received ceftiofur treatment.  Similarly, the steers in 
chlortetracycline-administered pens had a higher proportion of isolates that were not inhibited at 
higher concentrations of ceftiofur when compared to the isolates derived from pens in which 
chlortetracycline was not administered. 
 
4.5.       Discussion 
This study was designed to evaluate the effects of co-housing ceftiofur treated and non-
treated animals together, and also the effect of chlortetracycline treatment following ceftiofur 
treatment.  The effects were measured in terms of the phenotypic susceptibility profiles of NTS 
E. coli isolates and by evaluating the genotypic prevalence of specific resistance genes among 
these same NTS E. coli isolates.   
CCFA treatment on Day 0 selected for isolates with reduced susceptibility towards 
ceftiofur, both at genotypic and phenotypic levels.  There have been four other major published 
studies that have evaluated the effect of ceftiofur on cephalosporin resistance among enteric 
bacteria in cattle [115-117, 120].  Our results were quite similar to two of these earlier studies 
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[115-116].  The results from these two earlier studies indicated that CCFA was associated with a 
significant decrease in the total E. coli log10 CFU/g of feces in cattle.  This combined with a 
concurrent, though transient, expansion of the ceftiofur-resistant E. coli fraction following CCFA 
administration, resulted in the observed increase in prevalence [115-116].  In our study, the total 
E. coli CFU/g of feces also dropped by approximately 2 logs following CCFA treatment (data 
not shown) and remained lower than baseline for approximately 8-12 days [165].  A third study 
[120] also reported a similar transient increase in the animal-level prevalence of ceftiofur 
resistant E. coli immediately following ceftiofur treatment.  However, they did not observe a 
herd-level association between levels of ceftiofur use and increased shedding of extended 
spectrum cephalosporin resistant E. coli isolates.  These authors did not report the variations in 
the total E. coli load among samples collected during the study period; thus, their results could 
have been biased by ignoring the decrease in the background susceptible bacterial population.  
The fourth study [117] did not observe the animal-level associations between the ceftiofur use 
and prevalence of E. coli isolates with reduced susceptibility to ceftriaxone; however, while a 
significant herd-level association was associated with use versus non-use, no dose-response was 
detected among herds that used ceftiofur.  This was a cross-sectional prevalence study conducted 
in only 18 dairy herds.  Herds reporting ceftiofur use had a significantly higher prevalence of 
ceftriaxone resistance isolates among cattle fecal samples as compared to the herds that did not 
use ceftiofur.  The individual ceftiofur-treated cattle themselves did not exhibit an increased risk 
of shedding of E. coli isolates that had reduced susceptibility to ceftriaxone.  This may easily be 
attributed to the study design; the time duration between ceftiofur treatment and fecal sample 
collection was not controlled.  The increase in shedding of resistant isolates is typically found to 
be transitory and resistance levels usually return to baseline levels soon after selection pressures 
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are removed [115-116].  Therefore, the probability of finding a significant relationship between 
ceftiofur treatment and resistant bacteria post antimicrobial washout phase is low within a pen or 
herd.  On the other hand, herd-level associations suggest that a significant treatment- and time-
dependent  shift in ceftriaxone resistance baseline levels could occur once a product is first 
introduced into a herd [116].  
In contrast to our hypothesis, subsequent chlortetracycline treatment on Day 4 was not 
associated with a decrease in ceftiofur resistance as was seen in a previous study [11].  Instead, 
chlortetracycline greatly delayed the return of ceftiofur resistance to baseline levels following 
CCFA treatment.  Steers from both of the two studies were housed in the same research feedlot 
at West Texas A&M University.  The bacterial load was not quantified in the previous study so it 
was not possible to determine if chlortetracycline administration was associated with increasing 
the ceftiofur-resistant bacterial counts, or if there was merely a decrease in the susceptible 
bacterial population numbers.   In the present study, the total NTS E. coli load was quantified by 
measuring CFU counts (data not shown).  It was determined that, overall, chlortetracycline 
treatment slightly increased the NTS E. coli population.  Therefore, chlortetracycline treatment 
might also have led to an expansion of the ceftiofur resistant population instead.  This was in 
direct contrast to the hypothesis of the present study.   
Though the results were unexpected, they can best be explained based on simple 
mechanistic considerations of co-selection.  The genotypic analysis of the isolates obtained from 
this study revealed certain associations: chlortetracycline treatment in the absence of prior CCFA 
treatment significantly increased selection of the tet(B) gene over the tet(A) gene; the 2 tet genes 
were found to be negatively associated with each other; and tet(A) gene was found to be strongly 
associated with blaCMY-2 gene.  The chlortetracycline treatment in the previous study [11] may 
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have differentially selected for isolates with tet(B) genes over tet(A) gene.  The tet(B) and 
blaCMY-2 genes, not being significantly associated with each other, may have led to the finding of 
the previous study suggesting that chlortetracycline treatment resulted in a preferential selection 
of tetracycline resistant isolates over isolates co-resistant to both tetracycline and ceftiofur [11].  
However, in the present study, pens (or animals) receiving CCFA treatment selected for blaCMY-2 
positive isolates.  This expanded population likely also favored the tet(A) over tet(B) gene.  
Subsequent chlortetracycline treatment in the present trial may have further expanded this 
population (isolates harboring tet(A) along with blaCMY-2 genes); therefore, the reduction in 
ceftiofur resistance was not seen in these pens.  A major difference between the present study 
and that of Platt et al. (2008) was that the latter did not include prior ‘priming’ of the bacterial 
population with CCFA, either at the pen-level or of single individuals within those pens.    
Further, the ‘baseline’ prevalence of resistance to ceftiofur in the experimental feedlot has 
steadily increased over the years from 2003 through the present as traced from Lowrance et al. 
(2007) [116] through Platt et al. (2008) [11].  While one of our treatment groups very closely 
mimicked the previous study [11]; that is, where CCFA was administered to one among the 11 
steers within pens and then later on Day 4 all animals were exposed to chlortetracycline 
treatment, chlortetracycline in those pens too was not observed to reduce ceftiofur resistance.  
While the present study was designed to evaluate the effect of chlortetracycline as an 
intervention strategy to control ceftiofur resistance, the difference in study design when 
compared to Platt et al. may have caused some of the disparity.  However, it is extremely 
unlikely that it caused all of the disparity.  The E. coli isolates from both studies are being further 
characterized to better explain the study discrepancies, especially as relates to the earlier 
assumptions about the expected associations among tet(A), tet(B), and blaCMY-2 genes.  
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Over the entire study period, the frequency of phenotypically ceftiofur-resistant NTS E. 
coli isolates was always higher than the prevalence of isolates harboring blaCMY-2.  All earlier 
work in North America suggested that in feeder cattle populations the blaCMY-2 gene dominated 
and explained almost 100% of the resistance to ceftiofur [32, 158].  Obviously, as time moves 
forward there can always be other genetic determinants such as ESBL genes that will contribute 
to explain the disparity between phenotypic expression and genotype.  One previous study [64] 
indicated that the phenotypic and genotypic disparity could be attributed to other resistance 
determinants that were not tested for, or else could be due to the inability of the resistance genes 
to be turned on, in order to express phenotypic resistance.  The isolates in the present trial were 
further characterized to explain the observed discrepancy between phenotypic expression and 
genotype.  Twenty nine out of 88 steers tested positive for the blaCTX-M-32 gene over the study 
period [133].  The presence of the blaCTX-M-32 gene (28.8%) and ampC promoter mutation (0.5%) 
among NTS E. coli isolates almost completely explains the higher frequency of phenotypic 
ceftiofur resistance observed among isolates than was predicted by blaCMY-2 alone. 
CCFA treatment on Day 0 also selected for isolates with reduced susceptibility towards 
tetracycline.  A similar effect has been observed elsewhere [116, 166].  Also at the genotypic 
level, the prevalence of isolates harboring tetracycline resistance genes increased with CCFA 
treatment.  Chlortetracycline treatment further increased the frequency of tetracycline resistance.  
In this study, in the situation where the vast majority of steers in a pen were not primed with 
CCFA before chlortetracycline treatment, there was a differential selection of isolates harboring 
the tet(B) gene over tet(A) gene (Figure 4.6 D).  Chlortetracycline treatment effects on 
tetracycline resistance prevalence have been previously investigated [11, 167].  One of those 
studies [167] detected no significant increase in tetracycline resistance following 
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chlortetracycline treatment.  The authors contributed this to the gap in sampling time and a low 
initial prevalence of tetracycline resistance.  The other study [11] observed a significant increase 
in the likelihood of recovering tetracycline resistant isolates during and immediately following 
chlortetracycline administration.  The effect was transitory and the prevalence of the isolates 
with reduced susceptibility returned to baseline levels by 17 days post treatment. 
Pens in which all animals received CCFA treatment had significantly higher pen-level 
ceftiofur resistance as compared to pens in which only 1 among 11 animals were CCFA-treated.  
A previous study [8] in which ceftiofur treated and non-treated dairy cattle were co-housed 
together, reported a small increase in the blaCMY-2 gene copy numbers in fecal community DNA 
of the non-treated animals.  The authors attributed this effect to co-mingling of treated and non-
treated animals together.  Those results suggested horizontal transmission of bacterial 
strains/resistant determinants among the cattle that were housed together.  In our study, the non-
treated animals were expected to supply susceptible enteric bacteria into the environment within 
pens when treated and non-treated animals were housed together.  The treated animals also were 
in constant exposure to these susceptible bacteria.  These bacteria were expected to improve the 
microbial ecology of the treated animals by more rapidly returning the gut flora to baseline or 
equilibrium levels of resistance.  However, this present study was not designed to evaluate the 
animal-level effects of co-housing of treated and non-treated animals together; rather, the effects 
were assessed solely at the pen-level with sufficient statistical power to meet our stated 
objectives.  Further studies are required to establish any individual animal-level effects since 
insufficient statistical power is present in this study design to evaluate ‘mixing’ effects on the 
individual steers (n=4 total) receiving CCFA among 11 in a pen.  
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Antimicrobial pressure exerted both by CCFA and chlortetracycline selected for isolates 
with higher phenotypic MDR counts.  The effect of CCFA on co-selecting for other phenotypic 
antimicrobial resistances besides cephalosporins was more profound than was seen with 
chlortetracycline treatment.  At genotypic level, the presence of blaCMY-2 gene seemed to have a 
similar co-selection effect.  Isolates harboring the blaCMY-2 gene showed phenotypic resistance to 
a higher median number of antimicrobials when directly compared to isolates that did not harbor 
this gene.  Studies in the United States on Salmonella isolates derived from bovine, porcine, and 
human origin have indicated that the blaCMY-2 gene is usually located on a large IncA/C plasmid 
which harbors several other resistance genes [39-41].  Overall across all treatment groups and 
days, isolates harboring the tet(A) gene also showed phenotypic resistance against a higher 
median number of antimicrobials than those isolates carrying the tet(B) gene.  One previous 
study indicated instead an association of tet(B) genes with carriage more multiple resistance 
when compared to isolates harboring the tet(A) gene [63].  However, that was a cross-sectional 
prevalence study conducted at the farm-level.   In this randomized controlled trial, pretreatment 
Day 0 results suggested no significant difference between these 2 tet genes with respect to the 
carriage of multiple phenotypic antimicrobial resistance. CCFA administered on Day 0 selected 
for isolates harboring blaCMY-2 and this gene was associated with resistance against many other 
antimicrobials.  Importantly, the blaCMY-2 gene exhibited a positive association with the tet(A) 
gene.  There was likely to have been co-selection of isolates harboring blaCMY-2 and tet(A) genes 
because of the initial CCFA treatment.  It is also possible that isolates harboring the tet(A) gene 
demonstrated a higher multidrug phenotypic resistance count due to prior CCFA exposure and 
selection.  Therefore, in our study tet(A) positive isolates exhibited an overall higher multi-drug 
resistance profile when compared to tet(B) positive isolates. 
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A negative association was found between tet(A) and tet(B) genes among NTS E. coli 
isolates.  There were only 0.01 % (14 isolates) that harbored both the tet(A) and tet(B) gene.  
Previous studies have also indicated a negative association between these 2 tet genes [62-64].  
The negative association between the tetracycline resistance determinants has been suggested by 
some to be due to the incompatibility of the plasmids that carry these genes [168].   This has not 
been explored here, but work is underway in another laboratory that specializes in plasmid-
typing to examine this possibility using these 1,050 isolates.  There were only 3 isolates that 
harbored only the blaCMY-2 gene without the presence of either the tet(A) or tet(B) gene.  Earlier 
studies in North American cattle have reported that the blaCMY-2 gene is usually present with at 
least 1 other resistance gene.  However, we must acknowledge the high probability that there 
were other unexamined resistance factors present with the gene (beyond those few we 
examined); in fact, the phenotypic resistance profile suggests this was likely to have been the 
case, though not always to have been associated with the usual IncA/C plasmid [133, 169]. 
The present system of classifying antimicrobial susceptibility data into sensitive 
(susceptible) or resistant has been critiqued before [167, 170].  Such a system does not easily 
allow for analyzing the trends of changes in MIC values statistically.  The changes in the MIC 
values, both above and below an internationally accepted cut point (e.g. CLSI in North America; 
EUCAST in Europe), cannot readily be evaluated by the binary coding system.  In addition, such 
cut points are subject to change, especially when not based on epidemiological breakpoints.  
Survival analyses using non-parametric assumptions such as the Kaplan-Meier method [171-172] 
or else using Cox proportional hazards model [170]  have been proposed as alternative 
approaches for analyzing MIC data.  These methods use the entire dilution range of antimicrobial 
being tested and also deal effectively with the large number of right-censored observations (i.e., 
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those isolates that grow beyond the upper limit of antibiotic concentration included on 
commercially available plates).  The resulting survival curves illustrate and compare the 
proportion of bacteria that are uninhibited at each specific concentration of antimicrobial used, 
given that these bacteria have survived up to that concentration.  In addition, statistics such as the 
MIC50 (median MIC) and MIC90 (90th percentile MIC) are readily visible.  The drawback of a 
traditional survival approach is that the proportional hazard and the continuous time data 
assumptions are typically not met.  We instead analyzed our MIC data using a logistic model 
adapted for discrete-time survival data [164, 173-175].  Discrete time in our analysis was 
analogous to the specific concentrations (dilutions) of the antimicrobials on a log2 transformed 
scale (plus 4 to avoid negative values).  The recorded event was the inhibition of the bacterial 
growth at an observed minimum concentration.   
Fitted survival curves from the discrete-time regression model indicated that 
administration of both chlortetracycline and CCFA selected for higher proportions of isolates 
that could grow (i.e., were not inhibited) at higher in vitro ceftiofur concentrations.  The CCFA 
treatment effect on MIC distributions was much more profound than the chlortetracycline 
treatment effect.  Pens in which all animals received both CCFA and chlortetracycline treatments 
had 26% of the isolates that were still able to grow at the highest ceftiofur concentration on the 
NARMS panel (right censored on survival curve, MIC above the highest concentration used (8 
µg/ml)).  Meanwhile, isolates obtained from pens in which only 1 animal received CCFA 
treatment, and without subsequent chlortetracycline treatment, had almost all of their isolates 
inhibited by the highest ceftiofur concentration.  Differences also emerged among the treatment 
groups at much lower ceftiofur concentrations (see Figure 4.8: 2 and 3 on the X-axis, 
corresponding to concentrations of 0.25 and 0.5 µg/ml, respectively).  These curves provide 
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useful information and permit direct comparison of overall trends of the MIC distribution over 
the entire antimicrobial dilution range for all 4 groups, rather than simply comparing the 
proportion resistant/susceptible among 4 the treatment groups.     
In conclusion, chlortetracycline treatment resulted in an increased probability of 
recovering ceftiofur resistant isolates both at phenotypic and genotypic levels.  Chlortetracycline 
appears to greatly exacerbate ceftiofur resistance levels following CCFA therapy and therefore 
should be avoided, especially when used in sequence.  Unsurprisingly, pen-level ceftiofur 
resistance was lower in the groups with individual CCFA-treated and other non-treated animals 
co-housed together.  Further studies are required to establish the effect on the levels of 
antimicrobial resistance in individuals animals of co-housing antimicrobial-treated and non-
treated animals together at these and other varying ratios.  Such information will assist in 
determining some of the risks/benefits of individual- versus mass-therapy in production 
agriculture settings. 
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Drug Name Brand Name Dose (by BW)  Route of 
administration 
Treatment regimen(s) Days in  
regimen 
Ceftiofur crystalline-free acid  
(CCFA) 
Excede® 6.6 mg/kg Subcutaneous, 
base of ear 
1  
(Day 0) 
1 
Chlortetracycline (CTC) Aureomycin® 22 mg/kg Top-dressed 
on feed 
3  
(Days 4-8,10-14,16-20) 
5 
 
Table 4-1 Drugs, dosages, routes of administration, and treatment regimens. 
BW=body weight 
Excede®, (Zoetis Animal Health, NJ, U.S.A)  
Aureomycin®, chlortetracycline complex equivalent to 220.5 g of chlortetracycline/kg of premix, Alpharma™, Bridgewater, NJ 
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Gene 
name 
Primer Primer  Sequence Expected Product 
Size (bp) 
GenBank 
Accession no. * 
blaCMY-2 585F 5'- CAG ACG CGT CCT GCA ACC ATT AAA -3' 
454 a  AB212086 
1038R 5'- TAC GTA GCT GCC AAA TCC ACC AGT -3' 
tet(A) tet(A)(F) 5' -GCTACATCCTGCTTGCCTTC- 3' 
210 b X61367 
tet(A)(R) 5' -CATAGATCGCCGTGAAGAGG- 3' 
tet(B) tet(B) (F) 5' -TTGGTTAGGGGCAAGTTTTG- 3' 
659 b J01830 
tet(B) (R) 5' -GTAATGGGCCAATAACACCG- 3' 
 
Table 4-2 PCR primers used for PCR reactions. 
a Primer set used is from [106] 
b Primer set used is from [148] 
*Sequence used for primer design. 
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Table 4-3 Distributions of minimum inhibitory concentrations of 1,050 non-type-specific E. coli isolates against 15 antibiotics. 
*   Amoxicillin shown, clavulanic acid at 1/2X concentration that of amoxicillin.    
** Trimethoprim shown, sulfamethoxazole at 19X concentration that of trimethoprim.    
Unshaded areas indicate the dilution range of the Sensititre® plate used to test isolates. 
Vertical bars indicate the CLSI resistance breakpoint when available or else NARMS consensus breakpoint. 
Sum of numbers beyond vertical bar represents the percent of isolates which grew beyond the CLSI breakpoint (or, NARMS 
consensus breakpoint). These were considered as resistant in this study. 
Numbers in the shaded area indicate the percent of isolates that had an MIC greater than the highest concentration tested. 
1   Percent of the isolates that were resistant out of the total 1,050 non-type-specific E. coli isolates tested.    
2   95% Confidence interval was calculated using exact binomial method.    
∆    One-sided 97.5% confidence interval; used only when estimate was zero.    
NARMS 
Code Antimicrobial 
% 
Resistant1 95% CI2 Distribution of MICs in ug/ml (%) 
 
   
<0.015 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 >1024 
AMI Amikacin 0.00 0-0.004∆             0.10 5.43 80.29 14.00 0.19 0.00 0.00 0.00           
AMP Ampicillin 37.24 34.31-40.24               8.57 27.33 22.10 2.57 2.19 3.24  34.00           
AUG 
Amoxicillin 
/Clavulanic Acid* 18.67 16.35-21.16               5.81 15.05 43.43 13.52 3.52 15.52  3.14           
AXO Ceftriaxone 25.43 22.82-28.18           70.38 2.67 0.86 0.67 4.48 9.05 3.24 1.81 4.95  1.90         
CHL Chloramphenicol 23.43 20.90-26.11                 5.05 47.33 20.57 3.62 2.67  20.76           
CIP Ciprofloxacin 3.14 2.17-4.39   87.62 1.90 0.38 1.05 5.33 0.48 0.10 0.00 0.10  3.05                 
SXT 
Trimethoprim 
/Sulfamethoxazole** 4.00 2.90-5.37         54.00 37.81 4.00 0.00 0.19 0.29  3.71                 
FOX Cefoxitin 19.05 16.71-21.56             0.00 3.33 11.14 43.52 19.71 3.24 10.86  8.19           
GEN Gentamicin 0.95 0.46-1.74           1.24 67.33 22.10 0.95 3.52 3.90 0.29  0.67             
KAN Kanamycin 4.57 3.39-6.02                     86.95 3.05 5.43 2.10  2.48         
NAL Nalidixic Acid 9.62 7.90-11.57             0.19 7.90 75.71 4.86 0.86 0.86 0.95  8.67           
FIS Sulfisoxazole 31.33 28.54-34.24                       61.52 4.57 0.76 0.86 0.95 31.33     
STR Streptomycin 29.33 26.59-32.19                         70.67 9.24  20.10         
TET Tetracycline 61.14 58.12-64.10                   30.67 8.19 5.62 12.19  43.33           
TIO Ceftiofur 22.95 20.44-25.62         4.86 18.38 47.43 2.10 1.14 3.14 9.43  13.52               
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Figure 4.1 Schematic diagram of the study design. 
The two interventions were assigned in a two-way full factorial manner.  Number of pens to each treatment and number of 
animals within each pen are shown above. 
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 Figure 4.2 Frequency distribution of NTS E. coli by phenotypic multidrug resistance 
counts for the four treatment groups. 
(A) CCFA administered to all steers within pens without subsequent CTC administration 
at the pen level; (B) CCFA administered to one out of 11 steers within pens without 
subsequent CTC administration at the pen level; (C) CCFA administered to all steers 
within pens followed by CTC administered at the pen level; (D) CCFA administered to one 
out of 11 steers within pens followed by CTC administered at the pen level. 
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 Figure 4.3 Proportional Venn diagram illustrating the joint frequencies of three resistance 
genes among NTS E. coli isolates. 
Bolded numbers represent the marginal totals for each of the tet(A), tet(B), and blaCMY-2 
genes among 1,050 NTS E. coli isolates.  There was a total of 564 isolates that did not 
harbor any of the three genes.  
 
107 
 
 Figure 4.4 Boxplot of the phenotypic multidrug resistance count among NTS E. coli cross-
tabulated by different resistance gene combinations. 
Legend terms- cmy2, no cmy2, tetA, tetB, tetAtetB, neither tetA tetB in the figure are used 
for isolates that were found to be positive for blaCMY-2, negative for blaCMY-2, positive for 
tet(A), positive for tet(B), positive for both tet(A) and tet(B), and negative for tet(A) and 
tet(B) genes, respectively. 
Horizontal red bars indicate the median number of antimicrobials among each of gene 
combinations 
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 Figure 4.5 Prevalence of ceftiofur-resistant NTS E. coli isolates, modeled as marginal 
predicted probabilities, over days. 
Solid line represents the proportion of NTS E. coli isolates phenotypically resistant to 
ceftiofur  at ≥ 8 µg/ml. Dashed line represents the proportion of isolates harboring the 
blaCMY-2 gene.  The four treatment groups are (A) CCFA administered to all steers within 
pens without subsequent CTC administration at pen level; (B) CCFA administered to one 
out of 11 steers within pens without subsequent CTC administration at pen level; (C) 
CCFA administered to all steers within pens followed by CTC administered at pen level; 
(D) CCFA administered to one out of 11 steers within pens followed by CTC administered 
at pen level. 
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 Figure 4.6 Prevalence of tetracycline-resistant NTS E. coli isolates, modeled as marginal 
predicted probabilities, over days. 
Solid line represents the proportion of NTS E. coli isolates expressing phenotypic 
tetracycline resistance; dashed line represents the proportion of NTS E. coli isolates 
harboring the tet(A) gene; dotted line represents the proportion of NTS E. coli isolates 
harboring the tet(B) gene. The four treatment groups are: (A) CCFA administered to all 
steers within pens without subsequent CTC administration at pen level; (B) CCFA 
administered to one out of 11 steers within pens without subsequent CTC administration at 
pen level; (C) CCFA administered to all steers within pens followed by CTC administered 
at pen level; (D) CCFA administered to one out of 11 steers within pens followed by CTC 
administered at pen level.  
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Figure 4.7 Marginal predicted probabilities of NTS E. coli isolates to be (A) pan-
susceptible, (B) penta-resistant, and (C) resistant to 10 antimicrobials among the four 
treatment groups.  The four treatment groups are represented by four lines in all three sub 
graphs. See Figure 3.3 for treatment groups key.                                                           
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 Figure 4.8 Survival curve (predicted probabilities) of NTS E. coli isolates over the entire 
range of the ceftiofur concentration tested on a log scale. See Figure 3.3 for treatment 
groups key.
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Chapter 5 
Summary and Conclusions 
The research described in this dissertation focused on evaluating the effect of two 
treatment strategies on ceftiofur and tetracycline resistance among E. coli in feedlot cattle.  
Ceftiofur has been categorized as a critically important antimicrobial by the WHO because 
resistance to ceftiofur typically imparts ceftriaxone resistance among bacteria in humans; this is, 
due to shared resistance determinants.  In order to safeguard human health, the FDA in April 
2012 released an order of prohibition restricting certain extra-label uses of ceftiofur in animal 
agriculture.  In general, such prohibition orders may reduce the ability of the veterinarian or 
producer to prevent, control, and treat diseases among animals and potentially decrease the 
safety of food.  As a result, such actions may inadvertently affect both animal and human health.   
There is an urgent need to better understand those resistance dynamics which contribute 
to the emergence, dissemination, propagation, and persistence of resistance determinants among 
bovine gut microflora.  This understanding is essential for designing intervention strategies at 
animal, pen, and farm levels to best control or mitigate resistance against antimicrobials, 
especially those that are critically important for use in human medicine.   
This study was one effort towards evaluating the impact of two treatment strategies to 
better understand the ceftiofur resistance dynamics at both phenotypic and genotypic levels via 
culture-based and metagenome-based assays.  The first treatment strategy was evaluating pen 
versus individual-level CCFA treatments.  The CCFA treatment regimens employed mimicked 
either metaphylatic (pen-level) or therapeutic (individual animal) use in feedlot cattle to control 
or treat bovine respiratory disease, respectively.  Previous studies have reported a transient 
increase in the quantities of the ceftiofur resistance determinant blaCMY-2 gene among untreated 
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control cattle during the ceftiofur treatment phase; that is, when control and treated cattle were 
allowed to comingle at a 1:1 ratio.  This suggested that co-housed cattle can readily exchange 
bacteria or resistant determinants among themselves.  The non-treated animals in the pens in 
which individual animal received CCFA treatment were expected to serve as a ready source of 
susceptible bacterial strains and thus help to promote the re-colonization of treated animal with 
the ‘baseline’ microflora.  The second treatment strategy was based on either feeding or not 
feeding therapeutic doses of chlortetracycline, subsequent to the differential CCFA treatment.  
Chlortetracycline in our previous study [11] was found to significantly decrease the prevalence 
of ceftiofur resistant E. coli among the fecal bacteria populations.  Chlortetracycline treatment 
was expected to expedite the return of ceftiofur resistance to baseline levels among the enteric 
bacterial population, following differential CCFA administration.  The two strategies (co-
housing CCFA-treated with non-treated animals and chlortetracycline treatment) each were 
hypothesized to reduce both phenotypic and genotypic ceftiofur resistance among gut microflora 
in cattle.   
  As would be expected, ceftiofur resistance was indeed lower in the pens where only one 
animal was treated among the 11 pen-mates.  However, further studies are required to establish 
the animal-level effect of co-housing antimicrobial treated and non-treated animals together at 
varying ratios on the levels of antimicrobial resistance.  Pens in which all the animals received 
CCFA treatment demonstrated a significant increase in ceftiofur resistance, both in terms of 
ceftiofur resistance (blaCMY-2 and blaCTX-M) gene copies as well as the proportion of E. coli 
isolates that exhibited phenotypic ceftiofur resistance and also proportion of E. coli isolates that 
harbored blaCMY-2 gene.  CCFA treatment led to a significant decrease in the tetracycline 
resistance [tet(A) and tet(B)] gene copy numbers; however, there was a significant increase in 
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the proportion of E. coli isolates that exhibited phenotypic tetracycline resistance as well as the 
isolates that harbored the tet(A) and tet(B) genes.   
Pens receiving tetracycline treatment demonstrated a significant increase in the ceftiofur 
(blaCMY-2 and blaCTX-M) and tetracycline resistance [tet(A) and tet(B)] gene copies, irrespective of 
the prior differential CCFA treatment.  There was a significant increase in the proportion of E. 
coli isolates that exhibited phenotypic resistant to ceftiofur and tetracycline and also isolates that 
harbored blaCMY-2, tet(A), and tet(B) genes.  These study results demonstrate that 
chlortetracycline use did not lead to the hypothesized decrease in ceftiofur resistance in feedlot 
cattle.  Therefore, chlortetracycline is clearly contraindicated as an intervention when attempting 
to control resistance to critically important 3rd generation cephalosporins in feedlot cattle.   
Phenotypic and genotypic discrepancies in terms of ceftiofur resistance were observed 
among the E. coli isolates.  The proportion of E. coli isolates exhibiting phenotypic ceftiofur 
resistance was to found higher than the proportion of isolates that harbored the expected ceftiofur 
resistance determinant – the blaCMY-2 gene.  This blaCMY-2 gene had been previously been 
predominantly associated with, and was found to explain, almost 100% of the ceftiofur resistance 
in cattle in the United States.  These phenotypic and genotypic discrepancies were almost 
completely explained by the presence of blaCTX-M gene and ampC promoter mutations among the 
remaining phenotypically resistant E. coli isolates [133].  Both blaCMY-2 and blaCTX-M genes were 
quantified from fecal community DNA.  The blaCTX-M gene belongs to the family of genes 
encoding for extended-spectrum β-lactamases (ESBL).  This gene is widespread in Europe and 
the rest of the world, but reports of this gene in food-producing animals in the United States were 
rare and required enhanced broth enrichment techniques until now [52-53].   
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Distinct differences were also observed between results obtained from culture-based and 
metagenome-based assays.  Among fecal community DNA, CCFA treatment significantly 
decreased tetracycline resistance gene copies [tet(A) and tet(B)] whereas chlortetracycline 
treatment led to an increase in both of the ceftiofur resistance gene copies (blaCMY-2 and blaCTX-
M).  Among E. coli isolates, contrary to community DNA results, an increase in proportion of 
isolates harboring both tetracycline resistance genes (A and B) was observed following CCFA 
treatment and there was preferential selection of isolates harboring blaCMY-2 gene over blaCTX-M 
gene while receiving chlortetracycline treatment [132].   
These differences indicate the biases that could be introduced if conclusions pertaining to 
entire microbial populations are based solely on certain sentinel and culturable organisms.  
Presently, most antimicrobial resistance monitoring and surveillance systems across the world 
today test isolates and samples for antimicrobial resistance using culture-based methods.  
Extrapolating the results obtained from specific culturable organisms to the entire microbial 
community is unlikely to be valid as these results could incorrectly estimate the true target 
resistance load in the fecal microbiome.  The results from metagenome-based assays also have 
limitations; there may be multiple and varying amounts of target gene copies per bacterial cell 
(relative abundance) among different bacterial species.  The metagenome-based assay gives 
information about the overall target gene load in total community DNA.  The information about 
variation of specific bacterial species carrying target genes is not provided from this assay.  The 
results from either of the two approaches alone may not cover all aspects of antimicrobial 
resistance development, propagation and dissemination process.  Therefore, solely relying on 
either one of the approaches for making policies to control antimicrobial resistance in humans 
and animals by the regulatory bodies may not be appropriate.  A metagenome-based component 
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should be considered as part of a more holistic monitoring system in order to identify when 
contradictory or paradoxical results might be seen and in order to avoid bias.  Further, detection-
based methods (such as with broth enrichment or quanititative metagenome-based assays) should 
complement the prevalence-based assays to identify new and emerging threats.   
A quantitative real-time PCR performed on the community DNA enabled us to determine 
the effect of treatments on the resistance gene quantities in the entire microbial gene pool, and 
over the entire study period.  One of the challenges of this metagenome-based approach arises 
when the target gene quantities are below the quantification limit of the quantitative real-time 
PCR assay.  There are several ways proposed to deal with these missing data, such as single 
imputation, mean imputation, and complete case analysis.  A multiple imputation approach was 
found to be a useful tool to handle missing data in order to obtain valid inference from 
parametric statistical models whose assumptions depended on the integrity of underlying 
distributions.  We based our imputation model on unique animal identifier, sampling day, and the 
number of observations missing among the triplicate of each sample (i.e., 1, 2, or all 3 triplicates 
were missing).   
In addition to the associations among the antimicrobial treatment, resistance genes, and 
phenotypic resistance expression, the associations among resistance genes themselves also 
played an important role in understanding the emergence, persistence, and propagation of 
unrelated resistance determinants.  The complex resistance dynamics makes it necessary to 
deeply understand the system in order to design and implement effective intervention strategies 
to control antimicrobial resistance.  Overall, results from this study indicate that chlortetracycline 
use following CCFA treatment can readily exacerbate ceftiofur resistance and therefore should 
be avoided when used in sequence. 
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